<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>c58264exv2w1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv2w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;2.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">by and among
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VIKING HOLDINGS LLC,</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VIKING ACQUISITION CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">and<BR>
<BR>
<B>VIRTUAL RADIOLOGIC CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">May&nbsp;16, 2010
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; FONT-size: 1px">&nbsp;</DIV>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; FONT-size: 3pt">&nbsp;</DIV>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.01 The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.02 Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.03 Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.04 Effects of the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.05 Certificate of Incorporation and Bylaws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.06 Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 1.07 Officers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II CONVERSION OF SECURITIES; MERGER CONSIDERATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.01 Effect on Capital Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.02 Payment Procedures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.03 Exchange of Shares; Cancellation of Options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.04 Adjustments to Prevent Dilution</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 2.05 Dissenting Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.01 Corporate Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.02 Capitalization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.03 Authority; No Violation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.04 Consents and Approvals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.05 SEC Filings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.06 Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.07 Broker&#146;s Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.08 Absence of Certain Changes or Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.09 Legal Proceedings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.10 Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.11 Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.12 Compliance with Applicable Law; Permits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.13 Certain Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.14 Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.15 Anti-Takeover Provisions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.16 Company Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.17 Title to Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.18 Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.19 Environmental Liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.20 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.21 Labor Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.22 Certain Business Practices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.23 Opinion of Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 3.24 No Other Representations or Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.01 Corporate Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.02 Authority Relative to this Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.03 Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.04 Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.05 Brokers, Finders and Investment Bankers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.06 Parent Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.07 No Business Activities by Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.08 Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.09 Ownership of Company Common Stock; No Other Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.10 No Vote Required</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.11 Solvency</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.12 Section&nbsp;203 of the DGCL</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 4.13 Acknowledgement of Parent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V COVENANTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.01 Access to Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.02 Conduct of Business</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.03 Certain Changes or Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.04 No Control of Company&#146;s Business</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.05 Proxy Statement; Other Filings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.06 Stockholder Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.07 Further Actions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.08 Employees; Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.09 Indemnification; Directors&#146; and Officers&#146; Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.10 No Solicitation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.11 Standstill</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.12 Notification of Certain Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.13 Takeover Statutes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.14 Section&nbsp;16 Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.15 Delisting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.16 Additional Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 5.17 Cooperation with Financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI CONDITIONS TO CLOSING</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 6.01 Conditions to Each Party&#146;s Obligation to Effect the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 6.02 Conditions to Obligations of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 6.03 Conditions to Obligations of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII TERMINATION OF AGREEMENT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 7.01 Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 7.02 Company Termination Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 7.03 Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII NOTICES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX MISCELLANEOUS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.01 Non-survival of Representations and Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.02 Publicity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.03 Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.04 Entire Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.05 Assignment; Third Party Beneficiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.06 Governing Law</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.07 Waiver of Jury Trial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.08 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.09 Enforcement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.10 Captions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.11 Certain References</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.12 Guaranty by Parent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.13 Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.14 Amendment or Supplement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.15 Defined Terms</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SECTION 9.16 Interpretation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->iv<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT AND PLAN OF MERGER</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;), dated as of May&nbsp;16, 2010, is by
and among Viking Holdings LLC, a Delaware limited liability company (&#147;<U>Parent</U>&#148;), Viking
Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent
(&#147;<U>Merger Sub</U>&#148;), and Virtual Radiologic Corporation, a Delaware corporation (the
&#147;<U>Company</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>W I T N E S S E T H :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties intend that Merger Sub be merged with and into the Company, with the
Company surviving that merger upon the terms and subject to the conditions set forth herein;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board of Directors of the Company has (i)&nbsp;determined that the Merger is
advisable, fair and in the best interests of the Stockholders, (ii)&nbsp;adopted and approved the Merger
upon the terms and subject to the conditions set forth in this Agreement, and (iii)&nbsp;recommended
that the Stockholders adopt this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board of Managers of Parent, as the sole stockholder of Merger Sub, and Board of
Directors of Merger Sub, have adopted and approved this Agreement, the Merger and the transactions
contemplated by this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, contemporaneously with the execution and delivery of this Agreement, and as a
condition of the Company entering into this Agreement; Providence Equity Partners VI L.P. and
Providence Equity Partners VI-A L.P. (together, the &#147;<U>Guarantors</U>&#148;) are entering into a
guarantee in favor of the Company (the &#147;<U>Guarantee</U>&#148;) pursuant to which the Guarantors are
guaranteeing certain of the obligations of Parent and Merger Sub under this Agreement as set forth
in the Guarantee;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, contemporaneously with the execution of this Agreement, and as a condition and
inducement to Parent&#146;s and Merger Sub&#146;s entering into this Agreement, certain Stockholders have
entered into a Voting Agreement with the Parent and Merger Sub (the &#147;<U>Voting Agreement</U>&#148;);
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties desire to make certain representations, warranties, covenants and
agreements in connection with the Merger and the transactions contemplated by this Agreement and
also to prescribe certain conditions to the Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW THEREFORE, in consideration of the promises and the mutual agreements, covenants,
representations and warranties herein contained, the parties hereto agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I<BR>
THE MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.01 <U>The Merger</U>. Upon the terms and subject to the conditions set forth in
this Agreement, and in accordance with the DGCL, Merger Sub shall be merged with and into the
Company at the Effective Time (the &#147;<U>Merger</U>&#148;). At the Effective Time, the separate
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">corporate existence of Merger Sub shall cease, and the Company shall continue as the surviving
corporation (the &#147;<U>Surviving Corporation</U>&#148;) and a wholly owned subsidiary of Parent and shall
succeed to and assume all the rights and obligations of Merger Sub in accordance with the DGCL.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.02 <U>Closing</U>. The closing of the Merger (the &#147;<U>Closing</U>&#148;) will take
place at 10:00&nbsp;a.m., Minneapolis, Minnesota time, on the date (the &#147;<U>Closing Date</U>&#148;) that is
the second Business Day after the satisfaction or waiver (subject to applicable Law) of the
conditions set forth in Article&nbsp;VI (excluding conditions that, by their terms, are to be satisfied
on the Closing Date but subject to the satisfaction or waiver of such conditions), unless another
time or date is agreed to in writing by the parties hereto. The Closing shall be held at the
offices of Oppenheimer Wolff &#038; Donnelly LLP, Plaza VII, Suite&nbsp;3300, 45 South Seventh Street,
Minneapolis, Minnesota 55402, unless another place is agreed to in writing by the parties hereto.
For the purposes of this Agreement, &#147;<U>Business Day</U>&#148; shall mean each day other than a
Saturday, Sunday or any other day when commercial banks in New York, New York are authorized or
required by Law to close.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.03 <U>Effective Time</U>. Subject to the provisions of this Agreement, as soon as
practicable on the Closing Date, the parties shall prepare and execute a certificate of merger (the
&#147;<U>Certificate of Merger</U>&#148;) in accordance with the relevant provisions of the DGCL, and the
Surviving Corporation shall file the same with the Secretary of State of the State of Delaware.
The Merger shall become effective upon the filing of the Certificate of Merger with the Secretary
of State of the State of Delaware or at such subsequent time or date as Parent and the Company
shall agree and specify in the Certificate of Merger (the &#147;<U>Effective Time</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.04 <U>Effects of the Merger</U>. The effects of the Merger shall be as provided in
this Agreement and in the applicable provisions of the DGCL. Without limiting the generality of
the foregoing, at the Effective Time, all the property, rights, privileges, powers and franchises
of the Company and Merger Sub shall vest in the Surviving Corporation, and all debts, liabilities
and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the
Surviving Corporation, all as provided under the applicable Laws of the State of Delaware. If at
any time after the Effective Time any further action is necessary to vest in the Surviving
Corporation the title to all property or rights of Merger Sub or the Company, the authorized
officers and directors of the Surviving Corporation are fully authorized in the name of Merger Sub
or the Company, as the case may be, to take, and shall take, any and all such lawful action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.05 <U>Certificate of Incorporation and Bylaws</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;At the Effective Time, the certificate of incorporation of the Surviving Corporation shall
be amended and restated in the Merger to read in its entirety as set forth in <U>Exhibit&nbsp;A</U>
hereto and, as so amended and restated, shall be the certificate of incorporation of the Surviving
Corporation until thereafter amended as provided therein or by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;At the Effective Time, the bylaws of the Company as the Surviving Corporation shall be
amended and restated in the Merger to conform in their entirety to the bylaws of Merger Sub, as in
effect immediately prior to the Effective Time (except that all references to &#147;Merger Sub&#148; in the
bylaws of the Surviving Corporation shall be changed to refer
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to &#147;Virtual Radiologic Corporation&#148;) and as set forth in <U>Exhibit&nbsp;B</U> hereto and, as so
amended and restated, shall be the bylaws of the Surviving Corporation until thereafter amended as
provided therein or by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.06 <U>Directors</U>. The parties hereto shall take, and cause to be taken, all
actions necessary so that the directors of Merger Sub immediately prior to the Effective Time shall
be the directors of the Surviving Corporation until the earlier of their death, resignation or
removal in accordance with the Surviving Corporation&#146;s certificate of incorporation and the bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1.07 <U>Officers</U>. The officers of the Company immediately prior to the Effective
Time shall be the officers of the Surviving Corporation until the earlier of their death,
resignation or removal in accordance with the Surviving Corporation&#146;s certificate of incorporation
and the bylaws.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II<BR>
CONVERSION OF SECURITIES; MERGER CONSIDERATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.01 <U>Effect on Capital Stock</U>. At the Effective Time, by virtue of the Merger
and without any action on the part of the holder of any shares of capital stock of the Company,
Parent or Merger Sub:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Cancellation of Parent and Merger Sub Owned Company Common Stock; Treasury Stock</U>.
Each share of Company Common Stock that is owned by Parent, Merger Sub or any other subsidiary of
Parent or by the Company as treasury stock immediately prior to the Effective Time shall
automatically be canceled and retired and shall cease to exist and no consideration shall be
delivered in exchange therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Conversion of Company Common Stock</U>. Each share of Company Common Stock issued and
outstanding immediately prior to the Effective Time (not including, however, those shares of
Company Common Stock canceled pursuant to <U>Section&nbsp;2.01(a)</U> and Dissenting Shares) shall be
converted into and become the right to receive an amount in cash, without interest, equal to $17.25
(the &#147;<U>Merger Consideration</U>&#148;). All shares of Company Common Stock that have been converted
in the Merger into the right to receive the Merger Consideration shall be automatically canceled
and shall cease to exist, and the holders of Certificates which immediately prior to the Effective
Time represented shares of Company Common Stock shall cease to have any rights with respect to such
shares other than the right to receive the Merger Consideration in accordance with <U>Section
2.02</U> of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Capital Stock of Merger Sub</U>. Each share of capital stock of Merger Sub issued and
outstanding immediately prior to the Effective Time shall be converted into and become one validly
issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the
Surviving Corporation, and such shares shall constitute the only outstanding shares of capital
stock of the Surviving Corporation as of the Effective Time.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Stock Options and Restricted Stock</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;As of the Effective Time, each Company Stock Option shall be accelerated in full so that
it becomes fully vested as of the Effective Time and shall without any action on the part of any
holder of any Company Stock Option (an &#147;<U>Optionholder</U>&#148;) be canceled and the Optionholder
will receive as soon as reasonably practicable following the Effective Time a cash payment (without
interest) with respect thereto equal to the product of (A)&nbsp;the excess, if any, of the Merger
Consideration over the exercise price per share of such Company Stock Option and (B)&nbsp;the number of
shares of Company Common Stock issuable upon exercise of such Company Stock Option (collectively,
the &#147;<U>Option Consideration</U>&#148;). (For the avoidance of doubt, each Company Stock Option with
an exercise price at or above the Merger Consideration shall be canceled without any right to
receive any consideration therefor.) The Option Consideration shall be reduced by any withholding
or other Taxes that may be due as a result of the transactions contemplated by this <U>Section
2.01</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;As of the Effective Time, the restrictions on each restricted share of Company Common
Stock (collectively, the &#147;<U>Company Restricted Stock</U>&#148;) granted and then outstanding under the
Company Stock Plans shall, without any action on the part of the holder thereof, lapse immediately
prior to the Effective Time, and each such share of Company Restricted Stock shall be fully vested
in each holder thereof at such time, and each such share of Company Restricted Stock will be
treated at the Effective Time the same as, and have the same rights, including the right to receive
the Merger Consideration, and be subject to the same conditions as, each share of Company Common
Stock not subject to any restrictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The Board of Directors of the Company (the &#147;<U>Company Board</U>&#148;) or compensation
committee of the Company Board shall make such amendments and adjustments to make such
determinations with respect to, and cause to be taken such actions with respect to, the Company
Stock Options and Company Restricted Stock as are necessary and legally permissible to implement
the provisions of this <U>Section&nbsp;2.01</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.02 <U>Payment Procedures</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Parent to Make Merger Consideration and Option Consideration Available</U>. Prior to
the Effective Time, Parent shall (i)&nbsp;deposit, or shall cause to be deposited, with a bank or trust
company designated by Parent and reasonably acceptable to the Company (the &#147;<U>Paying Agent</U>&#148;)
in a separate fund (the &#147;<U>Exchange Fund</U>&#148;), for the benefit of (x)&nbsp;the holders of
certificates or evidence of shares in book-entry form which immediately prior to the Effective Time
evidence shares of Company Common Stock (each a &#147;<U>Certificate</U>&#148;) and (y)&nbsp;Optionholders, an
amount in cash sufficient to pay the aggregate Merger Consideration and the aggregate Option
Consideration (collectively, the &#147;<U>Aggregate Consideration</U>&#148;), and (ii)&nbsp;instruct the Paying
Agent to timely pay the Aggregate Consideration in accordance with this Agreement. The Aggregate
Consideration deposited with the Paying Agent pursuant to this <U>Section&nbsp;2.02</U> shall be
invested by the Paying Agent as directed by Parent; <U>provided</U>, <U>however</U>, that any
such investment or any payment of earnings from any such investment shall not (a)&nbsp;delay the receipt
by the holders of record of the Certificates of the Merger Consideration or otherwise impair such
holders&#146; rights hereunder, or (b)&nbsp;delay the receipt by the Optionholders of the Option
Consideration or otherwise impair such holders&#146; rights hereunder. Any interest or income produced
by such investments
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall not be deemed part of the Exchange Fund and shall be payable to the Surviving
Corporation. In the event that the funds in the Exchange Fund shall be insufficient to make the
payments contemplated by <U>Section&nbsp;2.01</U>, Parent shall promptly deposit, or cause to be
deposited, additional funds with the Paying Agent in an amount which is equal to the deficiency in
the amount required to make such payment. The Paying Agent shall cause the Exchange Fund to be (i)
held for the benefit of the holders of shares of Company Common Stock and Company Stock Options and
(ii)&nbsp;applied promptly to making the payments provided for in <U>Section&nbsp;2.01</U>. The Exchange
Fund shall not be used for any purpose that is not expressly provided for in this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>No Further Ownership Rights in Company Common Stock or Company Stock Options; Transfer
Books</U>. The Merger Consideration and the Option Consideration paid by the Paying Agent in
accordance with the terms of this <U>Section&nbsp;2.02</U> upon conversion of any shares of Company
Common Stock (including the Company Restricted Stock) or Company Stock Options, as applicable,
shall be deemed to have been paid in full satisfaction of all rights pertaining to such shares of
Company Common Stock or Company Stock Option, as applicable, and after the Effective Time there
shall be no further registration of transfers on the stock transfer books of the Surviving
Corporation of shares of Company Common Stock or Company Stock Options that were outstanding
immediately prior to the Effective Time. If, after the Effective Time, Certificates are presented
to the Surviving Corporation or the Paying Agent for any reason, they shall be canceled and
exchanged as provided in <U>Section&nbsp;2.03</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.03 <U>Exchange of Shares; Cancellation of Options</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As soon as reasonably practicable after the Effective Time, the Paying Agent shall mail to
each holder of record of a Certificate a form of letter of transmittal (which shall specify that
delivery shall be effected, and risk of loss and title to the Certificates shall pass, only upon
delivery of the Certificates to the Paying Agent) and instructions for use in effecting the
surrender of the Certificates in exchange for payment of the Merger Consideration. Upon proper
surrender of a Certificate for exchange and cancellation to the Paying Agent, together with a
properly completed letter of transmittal, duly executed, the holder of such Certificate shall be
entitled to receive in exchange therefor the Merger Consideration that such former holder has the
right to receive pursuant to the provisions of <U>Section&nbsp;2.01</U>, in each case, in respect of
the Certificate surrendered pursuant to the provisions of this <U>Section&nbsp;2.03</U>, and the
Certificate so surrendered shall forthwith be canceled.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If payment of the Merger Consideration is to be made to any Person other than the
registered holder of the Certificate surrendered in exchange therefor, it shall be a condition of
the payment thereof that the Certificate so surrendered shall be properly endorsed (or accompanied
by an appropriate instrument of transfer) and otherwise in proper form for transfer, and that the
Person requesting such exchange shall pay to the Paying Agent in advance of any transfer or other
similar Taxes required by reason of the payment of the Merger Consideration to any Person other
than the registered holder of the Certificate surrendered, or required for any other reason
relating to such holder or requesting Person, or shall establish to the reasonable satisfaction of
the Paying Agent that such Tax has been paid or is not payable.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;As soon as reasonably practicable after the Effective Time, the Paying Agent shall provide
notice to each Optionholder which includes (i)&nbsp;a description of the treatment of the Company Stock
Options in accordance with <U>Section&nbsp;2.01(d)</U> and (ii)&nbsp;payment of the Option Consideration
that such Person has the right to receive pursuant to the provisions of <U>Section&nbsp;2.01(d)</U> in
respect of such Optionholder&#146;s Company Stock Options.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Any portion of the Exchange Fund that remains unclaimed by the Stockholders or
Optionholders for one (1)&nbsp;year after the Effective Time shall be paid, at the request of Parent, to
Parent. Any Stockholder or Optionholder who has not theretofore complied with this <U>Section
2.03</U> or, with respect to the Optionholders, has not received their Option Consideration, shall
thereafter look only to Parent for payment of the Merger Consideration or Option Consideration
payable in respect of each share of Company Common Stock or Company Stock Option held by such
Person at the Effective Time as determined pursuant to this Agreement, in each case, without any
interest thereon. Notwithstanding anything to the contrary contained herein, none of Parent, the
Company, the Paying Agent, Merger Sub or any other Person shall be liable to any former Stockholder
or Optionholder for any amount properly delivered to a public official pursuant to applicable
abandoned property, escheat or similar laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;In the event any Certificate shall have been lost, stolen or destroyed, upon the making of
an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed
and, if required by Parent, the posting by such Person of a bond in such amount as Parent may
determine is reasonably necessary (such amount, however, not to exceed 20% of the Merger
Consideration that the Person is entitled to receive in respect of such lost, stolen or destroyed
Certificate) as indemnity against any claim that may be made against it with respect to such
Certificate, the Paying Agent will issue in exchange for such lost, stolen or destroyed Certificate
the Merger Consideration deliverable in respect thereof pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Parent, Surviving Corporation or the Paying Agent will be entitled to deduct and withhold
from the consideration otherwise payable pursuant to this Agreement or the transactions
contemplated hereby to any holder of Company Common Stock or Company Stock Options such amounts as
Parent, or any Affiliate thereof, Surviving Corporation or the Paying Agent are required to deduct
and withhold with respect to the making of such payment under the Code or any applicable provision
of U.S. federal, state, local or non-U.S. tax Law. To the extent that such amounts are properly
withheld by Parent, Surviving Corporation or the Paying Agent, (i)&nbsp;Parent, Surviving Corporation or
the Paying Agent will promptly pay such withheld amounts to the appropriate taxing authority, and
(ii)&nbsp;such withheld amounts will be treated for all purposes of this Agreement as having been paid
to the Stockholder or Optionholder in respect of whom such deduction and withholding were made by
Parent, Surviving Corporation or the Paying Agent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2.04 <U>Adjustments to Prevent Dilution</U>. Without limiting the other provisions
of this Agreement, in the event that the Company changes the number of shares of Company Common
Stock issued and outstanding prior to the Effective Time as a result of a reclassification, stock
split (including a reverse stock split), stock dividend or distribution, recapitalization, merger,
subdivision, issuer tender or exchange offer, or other similar transaction, the Merger
Consideration shall be equitably adjusted to reflect such change.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SECTION 2.05 <U>Dissenting Shares</U>.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Notwithstanding any provision of this Agreement to the contrary, shares of Company Common
Stock that are outstanding immediately prior to the Effective Time and held by Stockholders who
shall not have voted in favor of the Merger or consented thereto in writing and who are entitled to
demand and shall have demanded properly in writing appraisal for such shares in accordance, and who
comply in all respect with Section&nbsp;262 of the DGCL (collectively, the &#147;<U>Dissenting Shares</U>&#148;)
shall not be converted into or represent the right to receive the Merger Consideration set forth in
<U>Section&nbsp;2.01</U>. Such Stockholders shall be entitled to receive only the fair value of such
shares in accordance with the provisions of Section&nbsp;262 of the DGCL, unless and until such
Stockholders shall have failed to perfect or who effectively shall have withdrawn or lost their
rights to appraisal of such shares under Section&nbsp;262 of the DGCL. If any holder of Dissenting
Shares shall have failed to perfect or shall have withdrawn or lost his, her, or its rights to
appraisal of such shares under Section&nbsp;262 of the DGCL, such shares shall thereupon be deemed to
have been converted into and to have become exchangeable for, as of the Effective Time, the right
to receive the Merger Consideration specified in <U>Section&nbsp;2.01</U>, without any interest
thereon, upon surrender, in the manner provided in <U>Section&nbsp;2.03</U>, of the Certificate or
Certificates that formerly evidenced such Dissenting Shares and the Surviving Corporation and
Parent shall remain liable for the payment of the Merger Consideration for such shares of Company
Common Stock. At the Effective Time, any holder of Dissenting Shares shall cease to have any
rights with respect thereto except the rights provided in Section&nbsp;262 of the DGCL as described in
this <U>Section&nbsp;2.05</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall give Parent (i)&nbsp;prompt notice of any demands for appraisal received by
the Company, withdrawals of such demands and any other instruments served pursuant to the DGCL and
received by the Company and (ii)&nbsp;the opportunity to direct all negotiations and proceedings with
respect to demands for appraisal under the DGCL. The Company shall not, except with the prior
written consent of Parent, make any payment with respect to any demands for appraisal or offer to
settle or settle any such demands.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III<BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth (a)&nbsp;other than with respect to the representations and warranties in
<U>Section&nbsp;3.02</U> (Capitalization), in reasonable detail in the Company&#146;s filings with the
Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) required by the Securities Act or the
Exchange Act made between December&nbsp;31, 2008 and the date hereof (excluding any disclosure set forth
therein under the heading &#147;Risk Factors&#148; (other than factual information contained therein), any
disclosures in any section related to forward-looking statement to the extent that they are
primarily predictive, cautionary or forward looking in nature (other than factual information
contained therein), or any statements in Management&#146;s Discussion and Analysis) or (b)&nbsp;in the
disclosure schedule of the Company delivered to Parent concurrently herewith (the &#147;<U>Company
Disclosure Schedule</U>&#148;) (with specific reference to the section of this Agreement to which the
information stated in such Company Disclosure Schedule relates; provided that (i)&nbsp;disclosure in any
section of such Company Disclosure Schedule shall be deemed to be disclosed with respect to any
other Section of this Agreement to the extent that it is reasonably apparent from the face of such
disclosure that such disclosure is applicable or relevant to such other Section and (ii)&nbsp;the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">mere inclusion of an item in such Company Disclosure Schedule as an exception to a
representation or warranty shall not be deemed an admission that such item represents a material
exception or material fact, event or circumstance or that such item has had or would have a Company
Material Adverse Effect), the Company hereby represents and warrants to Parent and Merger Sub as
follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.01 <U>Corporate Organization</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware. The Company has the corporate power and corporate authority to
own or lease all of its properties and assets and to carry on its business as it is now being
conducted, and is duly licensed or qualified to do business in each jurisdiction in which the
nature of the business currently conducted by it or the character or location of the properties and
assets owned or leased by it makes such licensing or qualification necessary, except where the
failure to be so licensed or qualified would not reasonably be expected to result in a Company
Material Adverse Effect. As used in this Agreement, the term &#147;<U>Company Material Adverse
Effect</U>&#148; means any change, effect, event, circumstance, condition, occurrence or development
that, individually or in the aggregate, has had or would be reasonably likely to have a material
adverse effect on (i)&nbsp;the business, results of operations or condition (financial or otherwise) of
the Company, its Subsidiaries and the Affiliated Medical Practices taken as a whole or (ii)&nbsp;the
Company&#146;s ability to consummate the transactions contemplated hereby on a timely basis;
<U>provided</U>, <U>however</U>, that in determining whether a Company Material Adverse Effect
has occurred, there shall be excluded any effect on the Company, its Subsidiaries or the Affiliated
Medical Practices relating to or arising in connection with (A)&nbsp;the negotiation, execution,
delivery or public announcement or the pendency of this Agreement or the transactions contemplated
hereby or any actions expressly required to be taken in compliance herewith or otherwise with the
written consent of the other party hereto, including the impact thereof on the relationships of the
Company, any of its Subsidiaries or any of the Affiliated Medical Practices with customers,
vendors, licensors, consultants, employees or independent contractors or other third parties with
whom the Company, any of its Subsidiaries or any of the Affiliated Medical Practices has any
relationship and including any litigation brought by any Stockholder in connection with the
transactions contemplated hereby, (B)&nbsp;any change in the market price or trading volume of the
Company&#146;s securities or any effect resulting from any such change, (but not, in each case, the
underlying cause of such change or effect), (C)&nbsp;any failure by the Company to meet any projections
or forecasts for any period ending (or for which revenues or earnings are released) on or after the
date hereof (but not, in each case, the underlying cause of such change or effect), (D)&nbsp;any change
in federal, state, non-U.S. or local Law, regulations, policies or procedures, or interpretations
thereof, (E)&nbsp;any change in United States generally accepted accounting principles (&#147;<U>GAAP</U>&#148;)
or regulatory accounting requirements applicable or potentially applicable to the industries in
which the Company, its Subsidiaries or the Affiliated Medical Practices operate, (F)&nbsp;changes
generally affecting the industries in which the Company, its Subsidiaries or the Affiliated Medical
Practices operate, (G)&nbsp;changes in economic conditions (including changes in the prevailing interest
rates) in the United States, in any region thereof, or in any non-U.S. or global economy or (H)&nbsp;any
attack on, or by, outbreak or escalation of hostilities or acts of terrorism involving, the United
States, or any declaration of war by the United States Congress or any hurricane, earthquake or
other natural disaster, except to the extent such effects relating to or arising in connection with
matters described in (x)&nbsp;<font style="white-space: nowrap">clauses (D)</font>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and (F)&nbsp;above disproportionately affect the teleradiology industry, as compared to other
companies that conduct business in the healthcare industry and (y)&nbsp;clauses (E), (G)&nbsp;and (H)&nbsp;above
disproportionately affect the Company, its Subsidiaries, and Affiliated Medical Practices, taken as
a whole, as compared to other companies that conduct business in the industries in which the
Company, its Subsidiaries and Affiliated Medical Practices conduct business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The copies of the certificate of incorporation and bylaws of the Company which have
previously been made available to Parent are true, complete and correct copies of such documents as
in effect as of the date of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Subsidiary of the Company and each of the Affiliated Medical Practices (i)&nbsp;is duly
organized and validly existing as a corporation, partnership, limited liability company or other
entity, as the case may be, under the laws of its jurisdiction of organization, (ii)&nbsp;is duly
licensed or qualified to do business and is in good standing in all jurisdictions (whether federal,
state, local or non-U.S.) where its ownership or leasing of property or the conduct of its business
requires it to be so licensed or qualified and in which the failure to be so qualified would
reasonably be expected to result in, either individually or in the aggregate, a Company Material
Adverse Effect, and (iii)&nbsp;has all requisite corporate or other organizational power and authority
to own or lease its properties and assets and to carry on its business as now conducted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The minute books of the Company and each of its Subsidiaries and the Affiliated Medical
Practices previously made available to Parent contain true, complete and correct records in all
material respects of all meetings and other material corporate actions held or taken since January
1, 2008 of their respective stockholders, members, partners or other equity holders and Boards of
Directors or other governing bodies (including committees of their respective Boards of Directors
or other governing bodies) through the date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.02 <U>Capitalization</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The authorized capital stock of the Company consists of One Hundred Million (100,000,000)
shares of Company Common Stock and Six Million Three Hundred Seventy Thousand (6,370,000) shares of
preferred stock, par value $0.001 per share (the &#147;<U>Company Preferred Stock</U>&#148;). As of the
close of business on May&nbsp;13, 2010 (the &#147;<U>Capitalization Date</U>&#148;), there were Sixteen Million
Three Hundred Twenty-Six Thousand Six Hundred and Nine (16,326,609) shares of Company Common Stock
outstanding (including shares of Company Restricted Stock) and no shares of Company Preferred Stock
Outstanding. As of the close of business on the Capitalization Date, no shares of Company Common
Stock or Company Preferred Stock were reserved or to be made available for issuance, except as set
forth in <U>Section&nbsp;3.02(a)</U> of the Company Disclosure Schedule. All of the issued and
outstanding shares of Company Common Stock have been duly authorized and validly issued and are
fully paid, nonassessable and free of preemptive rights, with no personal liability attaching to
the ownership thereof. As of the date of this Agreement, except (i)&nbsp;as set forth in <U>Section
3.02(a)</U> of the Company Disclosure Schedule, (ii)&nbsp;pursuant to any cashless exercise provisions
of any Company Stock Options or pursuant to the surrender of shares to the Company or the
withholding of shares by the Company to cover Tax withholding obligations under the Company&#146;s stock
plans and arrangements set forth in <U>Section&nbsp;3.02(a)</U> of the Company Disclosure Schedule
(collectively, and in each case as the same may be amended to the date hereof, the &#147;<U>Company
Stock Plans</U>&#148;), and
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(iii)&nbsp;as set forth elsewhere in this <U>Section&nbsp;3.02(a)</U>, the Company does not have and is
not bound by any outstanding subscriptions, options, warrants, calls, commitments or agreements of
any character calling for the purchase or issuance of any shares of Company Common Stock or any
other equity securities of the Company or any securities representing the right to purchase or
otherwise receive any shares of the Company Common Stock (including any rights plan or agreement).
<U>Section&nbsp;3.02(a)</U> of the Company Disclosure Schedule sets forth a true, complete and correct
list of the aggregate number of shares of Company Common Stock issuable upon the exercise of each
Company Stock Option and each share of Company Restricted Stock granted under the Company Stock
Plans that was outstanding as of the Capitalization Date and the exercise price for each such
Company Stock Option. Since the Capitalization Date, the Company has not (i)&nbsp;issued or repurchased
any shares of its capital stock or any securities convertible into or exercisable for any shares of
its capital stock, other than upon the exercise of employee stock options granted prior to such
date and disclosed in this <U>Section&nbsp;3.02(a)</U> or pursuant to the surrender of shares to the
Company or the withholding of shares by the Company to cover Tax withholding obligations under the
Company Stock Plans, or (ii)&nbsp;issued or awarded any options, restricted shares or other equity-based
awards under the Company Stock Plans or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Section&nbsp;3.02(b)</U> of the Company Disclosure Schedule lists the name, jurisdiction of
organization, authorized and outstanding shares of capital stock and record and beneficial owners
of such capital stock for each Subsidiary of the Company. Except as set forth in <U>Section
3.02(b)</U> of the Company Disclosure Schedule, neither the Company nor any of its Subsidiaries
owns, directly or indirectly, any equity or similar interest in, or any interest convertible into
or exchangeable for, any equity or similar interest in, any corporation, partnership, joint venture
or other similar business association or entity. Except as set forth in <U>Section&nbsp;3.02(b)</U> of
the Company Disclosure Schedule, the Company owns, directly or indirectly, all of the issued and
outstanding shares of capital stock of or all other equity interests in each of the Company&#146;s
Subsidiaries free and clear of any Liens, and all of such shares are duly authorized and validly
issued and are fully paid, nonassessable and free of preemptive rights, with no personal liability
attaching to the ownership thereof. Neither the Company nor any of its Subsidiaries has or is bound
by any outstanding subscriptions, options, warrants, calls, commitments or agreements of any
character calling for the purchase, sale or issuance of any shares of capital stock or any other
equity security of any Subsidiary of the Company or any securities representing the right to
purchase or otherwise receive any shares of capital stock or any other equity security of any such
Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Section&nbsp;3.02(c)</U> of the Company Disclosure Schedule lists the name, jurisdiction of
organization, authorized and outstanding shares of capital stock or membership interests, as
applicable, for each of the Affiliated Medical Practices and the record and beneficial owners of
such capital stock and membership interests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.03 <U>Authority; No Violation</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company has full corporate power and corporate authority to execute and deliver this
Agreement and, subject to receipt of the Company Required Vote, to consummate the transactions
contemplated hereby. The Company Board at a duly held meeting has (i)&nbsp;determined that this
Agreement and the Merger are in the best interests of the Company
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and the Stockholders and declared this Agreement and the Merger to be advisable, (ii)&nbsp;approved
the Merger, the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby and (iii)&nbsp;subject to <U>Section&nbsp;5.10</U>, recommended that the Stockholders
adopt this Agreement and directed that this Agreement be submitted for consideration by the
Stockholders at the Company Stockholder Meeting. Except for the adoption of this Agreement by the
affirmative vote of a majority of the outstanding shares of Company Common Stock entitled to vote
at the Company Stockholder Meeting or by written consent of a majority of the outstanding shares of
Company Common Stock (the &#147;<U>Company Required Vote</U>&#148;), no other corporate proceedings on the
part of the Company are necessary to approve this Agreement or to consummate the transactions
contemplated hereby. This Agreement has been duly and validly executed and delivered by the Company
and (assuming due authorization, execution and delivery by Parent and Merger Sub) constitutes a
valid and binding obligation of the Company, enforceable against the Company in accordance with its
terms, except as enforcement may be limited by general principles of equity whether applied in a
court of law or a court of equity and by bankruptcy, insolvency and similar laws affecting
creditors&#146; rights and remedies generally (the &#147;<U>Bankruptcy and Equity Exceptions</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the execution and delivery of this Agreement by the Company nor the consummation
by the Company of the transactions contemplated hereby (including the Merger), nor compliance by
the Company with any of the terms or provisions hereof, will (i)&nbsp;violate any provision of the
certificate of incorporation or bylaws of the Company or any of the similar governing documents of
any of its Subsidiaries or the Affiliated Medical Practices or (ii)&nbsp;assuming that the consents,
approvals and filings referred to in <U>Section&nbsp;3.04</U> are duly obtained or made, (A)&nbsp;violate
any statute, code, ordinance, rule, regulation, judgment, order, writ, decree or injunction
applicable to the Company, any of its Subsidiaries, any of the Affiliated Medical Practices or any
of their respective properties or assets, or (B)&nbsp;violate, conflict with, result in a breach of any
provision of, or require redemption or repurchase or otherwise require the purchase or sale of any
securities, constitute a default (or an event which, with notice or lapse of time, or both, would
constitute a default) under, result in the termination of or a right of termination or cancellation
under, accelerate the performance required by, or result in the creation of any Lien upon any of
the properties or assets of the Company, any of its Subsidiaries or any of its Affiliated Medical
Practices under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture,
deed of trust, license, lease, agreement or other instrument or obligation to which the Company,
any of its Subsidiaries or any of its Affiliated Medical Practices is a party, or by which they or
any of their respective properties or assets may be bound or affected, except (in the case of
clause (ii)&nbsp;above) for such violations, conflicts, breaches, defaults or other events which, either
individually or in the aggregate, would not reasonably be expected to result in a Company Material
Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.04 <U>Consents and Approvals</U>. No consents or approvals of, or filings or
registrations with, any federal or state court, administrative agency or commission or other
governmental authority or instrumentality or self-regulatory organization of competent jurisdiction
(each a &#147;<U>Governmental Entity</U>&#148;) or with any third Person are necessary in connection with
the execution and delivery by the Company of this Agreement or the consummation by the Company of
the Merger and the other transactions contemplated hereby, except for (a)&nbsp;any notices required to
be filed under the HSR Act, (b)&nbsp;the filing with the SEC of a proxy statement in definitive form
relating to the Company Stockholder Meeting (the &#147;<U>Proxy Statement</U>&#148;) as well
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">as any other filings required to be made with the SEC pursuant to the Securities Act or the
Exchange Act, (c)&nbsp;any filings required by the rules and regulations of the Nasdaq Stock Market (d)
the filing of the Certificate of Merger in accordance with the DGCL, and (e)&nbsp;consents or approvals
of, or filings or registrations with, Governmental Entities or third Persons, the failure of which
to be obtained or made would not be reasonably expected to result in, individually or in the
aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.05 <U>SEC Filings</U>. The Company has filed all forms, reports, statements,
certifications and other documents (including all exhibits, amendments and supplements thereto)
required to be filed by it with the SEC since January&nbsp;1, 2008 (collectively, the &#147;<U>Company SEC
Reports</U>&#148;). Each of the Company SEC Reports, as amended prior to the date of this Agreement,
complied as to form in all material respects with the applicable requirements of the Securities Act
of 1933, as amended, and the rules and regulations of the SEC promulgated thereunder (the
&#147;<U>Securities Act</U>&#148;) and the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the SEC promulgated thereunder (the &#147;<U>Exchange Act</U>&#148;), each as in effect on
the date so filed (or if amended or superseded by a filing prior to the date of this Agreement,
then on the date of such subsequent filing). None of the Company SEC Reports contained, when filed
or, if amended or supplemented prior to the date hereof, as of the date of such amendment or
supplement, any untrue statement of a material fact or omitted to state a material fact required to
be stated or incorporated by reference therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.06 <U>Financial Statements</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of the financial statements included (or incorporated by reference) in the Company
SEC Reports (including the related notes, where applicable), after giving effect to any
restatements made by the Company prior to the date of this Agreement, fairly present in all
material respects (subject, in the case of the unaudited statements, to normal recurring
adjustments, none of which would be reasonably expected to result in, individually or in the
aggregate, a Company Material Adverse Effect) the results of the consolidated operations and
changes in stockholders&#146; equity and consolidated financial position of the Company, its
Subsidiaries and the Affiliated Medical Practices for the respective fiscal periods or as of the
respective dates therein set forth. Each of such financial statements (including the related notes,
where applicable), after giving effect to any restatements made by the Company prior to the date of
this Agreement, complies in all material respects with applicable accounting requirements and with
the published rules and regulations of the SEC with respect thereto and each of such financial
statements (including the related notes, where applicable) has been prepared in accordance with
GAAP, as in effect on the date or for the period with respect to which such principles are applied,
in all material respects consistently applied during the periods involved, except in each case as
indicated in such statements or in the notes thereto or, in the case of unaudited statements, as
permitted by Form 10-Q. The books and records of the Company, its Subsidiaries and the Affiliated
Medical Practices have been, and are being, maintained in all material respects in accordance with
GAAP and any other applicable legal and accounting requirements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The records, systems, controls, data and information of the Company, its Subsidiaries and
the Affiliated Medical Practices are recorded, stored, maintained and operated
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">under means (including any electronic, mechanical or photographic process, whether
computerized or not) that are under the exclusive ownership and direct control of the Company, its
Subsidiaries or the Affiliated Medical Practices or accountants (including all means of access
thereto and therefrom), except for any non-exclusive ownership and non-direct control that would
not reasonably be expected to have a material adverse effect on the system of internal accounting
controls described below in this <U>Section&nbsp;3.06(b)</U>. The Company (i)&nbsp;has established and
maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e) of the
Exchange Act) to ensure that material information relating to the Company, including its
consolidated Subsidiaries and the Affiliated Medical Practices, is made known to the chief
executive officer and the chief financial officer of the Company by others within those entities
and (ii)&nbsp;has disclosed, based on its most recent evaluation prior to the date hereof, to the
Company&#146;s outside auditors and the audit committee of the Company Board (A)&nbsp;any significant
deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting (as defined in Rules&nbsp;13a-15(f) and 15d-15(f) of the Exchange Act) which are reasonably
likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial
information and (B)&nbsp;any fraud, whether or not material, that involves management or other employees
who have a significant role in the Company&#146;s internal controls over financial reporting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.07 <U>Broker&#146;s Fees</U>. Except for the Company&#146;s engagement of Goldman Sachs &#038;
Co., neither the Company, any of its Subsidiaries nor any of the Affiliated Medical Practices has
employed any broker or finder or incurred any liability for any broker&#146;s fees, commissions or
finder&#146;s fees in connection with any of the transactions contemplated by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.08 <U>Absence of Certain Changes or Events</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as set forth in <U>Section&nbsp;3.08(a)</U> of the Company Disclosure Schedule, since
January&nbsp;1, 2010, no event has occurred which would reasonably be expected to result in,
individually or in the aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in <U>Section&nbsp;3.08(b)</U> of the Company Disclosure Schedule or as
contemplated by this Agreement or permitted under <U>Section&nbsp;5.03</U>, since January&nbsp;1, 2010, the
Company, its Subsidiaries and the Affiliated Medical Practices have carried on their respective
businesses in all material respects in the Ordinary Course of Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.09 <U>Legal Proceedings</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As of the date of this Agreement, none of the Company, its Subsidiaries or the Affiliated
Medical Practices is a party to any, and there are no pending or, to the Knowledge of the Company,
threatened, material legal, administrative, arbitral or other proceedings, claims, actions or
governmental or regulatory investigations of any nature (i)&nbsp;against the Company, any of its
Subsidiaries or any of the Affiliated Medical Practices that would reasonably be expected to result
in, individually or in the aggregate, a Company Material Adverse Effect or (ii)&nbsp;challenging the
validity or propriety of the transactions contemplated by this Agreement. &#147;<U>Knowledge of the
Company</U>&#148; means the actual knowledge of the directors and executive officers of the Company
listed in <U>Section&nbsp;3.09(a)</U> of the Company Disclosure Schedule, in each
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">case without such individual being obligated to conduct any special inquiry or investigation
into the affairs or records of the Company, its Subsidiaries or the Affiliated Medical Practices.
The directors and executive officers of the Company listed in <U>Section&nbsp;3.09(a)</U> of the
Company Disclosure Schedule shall not be deemed to have knowledge (actual, constructive or
otherwise) of any fact, event, condition or occurrence known or deemed to be known by any other
person other than as expressly set forth in the foregoing sentence.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As of the date of this Agreement, except as set forth in <U>Section&nbsp;3.09(b)</U> of the
Company Disclosure Schedule, none of the Company, any of its Subsidiaries, any of the Affiliated
Medical Practices or any of their respective businesses or properties are subject to or bound by
any injunction, order, judgment, decree or regulatory restriction of any Governmental Entity
specifically imposed upon the Company, any of its Subsidiaries, any of the Affiliated Medical
Practices or their respective assets which would reasonably be expected to result in, individually
or in the aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.10 <U>Taxes</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as set forth in <U>Section&nbsp;3.10(a)</U> of the Company Disclosure Schedule: (i)
each of the Company, its Subsidiaries and the Affiliated Medical Practices has (A)&nbsp;duly and timely
filed (including pursuant to applicable extensions granted without penalty) all material Tax
Returns required to be filed by it, and such Tax Returns are true, correct and complete in all
material respects, (B)&nbsp;timely paid in full all material amounts of Taxes due and owing (whether or
not shown on any Tax Return) except for Taxes being contested in good faith by appropriate
proceedings and for which adequate reserves have been established on the latest audited financial
statements in accordance with GAAP, and (C)&nbsp;made adequate provision in its financial statements in
accordance with GAAP for payment of all material amounts of Taxes that are not yet due and payable;
(ii)&nbsp;no material deficiencies for any Taxes have been proposed, asserted or assessed in writing
against the Company, any of its Subsidiaries or any of the Affiliated Medical Practices which
deficiencies have not since been resolved; and (iii)&nbsp;there are no material Liens for Taxes upon any
of the assets of the Company, its Subsidiaries or the Affiliated Medical Practices except for
statutory liens for current Taxes not yet due, or Liens for Taxes that are being contested in good
faith by appropriate proceedings and for which adequate reserves have been established on the
latest financial statements in accordance with GAAP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in <U>Section&nbsp;3.10(b)</U> of the Company Disclosure Schedule, none of
the Company, its Subsidiaries or the Affiliated Medical Practices (i)&nbsp;is or has ever been a member
of an &#147;affiliated group&#148; (other than, with respect to the Company, a group the common parent of
which is the Company) filing an affiliated, consolidated, combined or unitary Tax Return, or (ii)
has any liability for Taxes of any Person (other than, with respect to, the Company, and its
Subsidiaries) arising from the application of Treasury Regulation section 1.1502-6 or any analogous
provision of state, local or non-U.S. Law, as a transferee or successor, or by contract (other than
customary Tax indemnifications contained in commercial agreements the primary purpose of which does
not relate to Taxes).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;No closing agreement pursuant to Section&nbsp;7121 of the Code (or any similar provision of
state, local or non-U.S. Law) has been entered into by or with respect to the Company or any of its
Subsidiaries or the Affiliated Medical Practices.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;None of the Company, its Subsidiaries or the Affiliated Medical Practices has been a
&#147;distributing corporation&#148; or a &#147;controlled corporation&#148; in any distribution occurring during the
last two (2)&nbsp;years in which the parties to such distribution treated the distribution as one to
which Section&nbsp;355 of the Code is applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;All Taxes required to be withheld, collected or deposited by or with respect to the
Company and each Subsidiary and Affiliated Medical Practice have been timely withheld, collected or
deposited as the case may be, and to the extent required, have been paid to the relevant taxing
authority, except for failures to so withhold, collect or deposit that are immaterial, individually
and in the aggregate, or for which adequate reserves have been established in accordance with GAAP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Neither the Company nor any of its Subsidiaries or the Affiliated Medical Practices (i)
has granted any waiver of any federal, state, local or non-U.S. statute of limitations with respect
to, or granted any extension of a period for the assessment of, any Tax, which waiver or extension
has not since expired; (ii)&nbsp;is a party to any Tax allocation or sharing agreement; (iii)&nbsp;has
engaged in any listed transaction described in Treasury Regulation section 1.6011-4(b)(2); or (iv)
has received written notice from a Governmental Entity in a jurisdiction where the Company, any of
its Subsidiaries or the Affiliated Medical Practices do not file Tax Returns claiming that the
Company, any of its Subsidiaries or the Affiliated Medical Practices is or may be subject to
taxation by that jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;As used herein, &#147;<U>Taxes</U>&#148; shall mean all taxes, charges, levies, fees or other
assessments imposed by any United States federal, state, local or non-U.S. taxing authority,
including income, excise, property, sales, transfer, franchise, payroll, withholding, social
security or other similar taxes, including any interest, penalties or additions to tax attributable
thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;As used herein, &#147;<U>Tax Return</U>&#148; shall mean any return, report, information return or
other document (including any related or supporting information) filed or required to be filed with
any taxing authority with respect to Taxes, including all information returns relating to Taxes of
third parties, any claims for refunds of Taxes and any amendments or supplements to any of the
foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.11 <U>Employee Benefit Plans</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Section&nbsp;3.11(a)</U> of the Company Disclosure Schedule sets forth a true and complete
list or description of each material employee benefit plan, arrangement, policy, program or
agreement and any amendments or modifications thereof (including any stock purchase, stock option,
stock incentive, severance, employment, change-in-control, health/welfare plans, fringe benefit,
bonus, incentive, deferred compensation, pension and other agreements, programs, policies and
arrangements, whether formal or informal, oral or written, whether or not subject to the Employee
Retirement Income Security Act of 1974, as amended (&#147;<U>ERISA</U>&#148;)) that is sponsored, maintained
or contributed to as of the date of this Agreement by the Company or any of its Subsidiaries or the
Affiliated Medical Practices (collectively, the &#147;<U>Company Benefit Plans</U>&#148;).
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in <U>Section&nbsp;3.11(b)</U> of the Company Disclosure Schedule, the
Company has previously provided or made available to Parent true and complete copies of each of the
Company Benefit Plans and each of the following (if applicable): (i)&nbsp;the most recent actuarial
valuation report for each Company Benefit Plan, (ii)&nbsp;the most recent determination letter from the
IRS for each Company Benefit Plan, (iii)&nbsp;any summary plan description by the Company, its
Subsidiaries or the Affiliated Medical Practices concerning the extent of the benefits provided
under a Company Benefit Plan, (iv)&nbsp;any related trust agreement or other funding instrument, and (v)
the most recent Form&nbsp;5500, including the attached schedules, required to have been filed with the
IRS.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the Company nor any Person treated as a single employer with the Company under
Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code maintains or is required to contribute to any Company
Benefit Plan that (i)&nbsp;is a &#147;multiemployer plan&#148; as defined in Sections&nbsp;3(37) of ERISA, (ii)&nbsp;is
subject to the funding requirements of Section&nbsp;412 of the Code or Title IV of ERISA, or (iii)
provides for post-retirement medical, life insurance or other welfare-type benefits (other than as
required by Part&nbsp;6 of Subtitle B of Title I of ERISA or Section&nbsp;4980B of the Code or under a
similar state Law).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company Benefit Plans and their related trusts intended to qualify under Sections&nbsp;401
and 501(a) of the Code are subject to current favorable determination or opinion letters from the
IRS and, to the Knowledge of the Company, nothing has occurred that is reasonably likely to result
in the revocation of such letter, except where the failure to so comply would not reasonably be
expected to result in, individually or in the aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company Benefit Plans have been maintained and administered in all material respects
in accordance with their terms and applicable laws except where the failure to so comply would not
reasonably be expected to result in, individually or in the aggregate, a Company Material Adverse
Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;There are no suits, actions, disputes, claims (other than routine claims for benefits),
arbitrations, administrative or other proceedings pending or, to the Knowledge of the Company,
threatened with respect to any Company Benefit Plan or any related trust or other funding medium
thereunder or with respect to the Company as the sponsor or fiduciary thereof or with respect to
any other fiduciary thereof, which would reasonably be expected to have a Company Material Adverse
Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;None of the Company, its Subsidiaries or Affiliated Medical Practices is a party to any
contract, agreement, plan or arrangement covering any employee or former employee thereof that,
individually or collectively, could give rise to imposition of any excise tax or the payment of any
amount that would not be deductible by reason of Section&nbsp;280G of the Code. Except (i)&nbsp;as set forth
in <U>Section&nbsp;3.11(g)</U> of the Company Disclosure Schedule or (ii)&nbsp;as would not result in any
Taxes or other liabilities to the Company, its Subsidiaries or any employees of the Company or its
Subsidiaries in excess of $100,000, the consummation of the transactions contemplated by this
Agreement will not by itself (x)&nbsp;result in any payment of severance or other compensation becoming
due to any current or former employee or independent contractor, (y)&nbsp;increase any benefits under
any Company Benefit Plan, or (z)&nbsp;result
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in the acceleration of the time of payment, vesting or funding of any such benefits under any
Company Benefit Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.12 <U>Compliance with Applicable Law; Permits</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;None of the Company, its Subsidiaries or the Affiliated Medical Practices is in violation
of, or has violated, any applicable provisions of any applicable Law or requirements of any
Governmental Entity, except for any such violations which, individually or in the aggregate, have
not had and would not reasonably be expected to have a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the Company, its Subsidiaries and the Affiliated Medical Practices holds all
permits, licenses, approvals, authorization, registrations, franchises, certificates,
notifications, exemptions and other authorizations from all Governmental Entities
(&#147;<U>Permits</U>&#148;) required to operate and to carry on its business as currently conducted, except
where the failure to hold such Permits, individually or in the aggregate, has not had and would not
reasonably be expected to have a Company Material Adverse Effect. All Permits are in all material
respects, in full force and effect and since January&nbsp;1, 2008, none of the Company, its Subsidiaries
or the Affiliated Medical Practices has received any written notice from any Governmental Entity
asserting that the Company or any of its Subsidiaries or the Affiliated Medical Practices is not in
material compliance with any Law or material Permit or threatening to suspend, revoke, revise,
limit or terminate any material Permit held by the Company or any of its Subsidiaries or the
Affiliated Medical Practices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except where the failure to do so would not reasonably be expected to have a Company
Material Adverse Effect, each of the physicians who provides radiology services for the Company or
any of its Subsidiaries or the Affiliated Medical Practices (i)&nbsp;is, solely with respect to
providing radiology services for the Company or any of its Subsidiaries or the Affiliated Medical
Practices, licensed to practice medicine in each of the states in which (1)&nbsp;such physician
practices medicine and (2)&nbsp;the patients for which such physician provides radiology interpretations
received imaging services, (ii)&nbsp;has, solely with respect to providing radiology services for the
Company or any of its Subsidiaries or the Affiliated Medical Practices, obtained medical staff
privileges at any hospitals at which such physician provides radiology interpretations, and (iii)
to the Knowledge of the Company, is not now or has never been during the time such physician has
performed radiology services for the Company or any of its Subsidiaries or the Affiliated Medical
Practices, excluded by any Federal Health Care Program.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding anything contained in this <U>Section&nbsp;3.12</U>, no representation or
warranty shall be deemed to be made in this <U>Section&nbsp;3.12</U> in respect of the matters
referenced in <U>Sections&nbsp;3.05</U> or <U>3.06</U> or in respect of environmental, Tax, employee
benefits or labor Law matters, each of which matters is addressed by other sections of this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.13 <U>Certain Contracts</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except for this Agreement, the Company Benefit Plans and as set forth in <U>Section
3.13(a)</U> of the Company Disclosure Schedule, as of the date hereof, none of the Company, its
Subsidiaries or the Affiliated Medical Practices is a party to nor is bound by any
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contract, arrangement, commitment or understanding (whether written or oral) (i)&nbsp;which is a
material contract (as defined in Item&nbsp;601(b)(10) of Regulation&nbsp;S-K of the SEC) to be performed
after the date of this Agreement, (ii)&nbsp;which materially restricts the rights of the Company, its
Subsidiaries or the Affiliated Medical Practices to compete in any line of business in any
geographic area or with any Person, or which requires exclusive referrals of business or requires
the Company, its Subsidiaries or the Affiliated Medical Practices to offer specified products or
services to their customers on a priority or exclusive basis, (iii)&nbsp;with or to a labor union or
guild (including any collective bargaining agreement), (iv)&nbsp;which relates to the incurrence of
Indebtedness in the principal amount of $100,000 or more, (v)&nbsp;which grants any Person a right of
first refusal, right of first offer or similar right with respect to any material properties,
assets or businesses of the Company, its Subsidiaries or the Affiliated Medical Practices, or (vi)
which involves the purchase or sale of assets with an aggregate purchase price of $100,000 or more.
Each contract, arrangement, commitment or understanding of the type described in this <U>Section
3.13(a)</U>, whether or not publicly disclosed in the Company SEC Reports filed prior to the date
hereof or set forth in <U>Section&nbsp;3.13(a)</U> of the Company Disclosure Schedule, is referred to
herein as a &#147;<U>Company Contract</U>&#148;, and none of the Company, its Subsidiaries or the Affiliated
Medical Practices has received written notice of any material violation of a Company Contract by
any of the other parties thereto. The Company has made available all contracts which involved
payments by the Company, its Subsidiaries or the Affiliated Medical Practices in fiscal year 2009
of more than $100,000 or which could reasonably be expected to involve such payments during fiscal
year 2010 of more than $100,000, other than any such contract that is terminable at will on sixty
(60)&nbsp;days or less notice without payment of a penalty in excess of $50,000, or other than any
contract entered into on or after the date hereof that is permitted under the provisions of
<U>Section&nbsp;5.03</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in <U>Section&nbsp;3.13(b)</U> of the Company Disclosure Schedule, (i)
each Company Contract is valid and binding on the Company, its Subsidiaries and the Affiliated
Medical Practices, as applicable, and in full force and effect (other than due to the ordinary
expiration of the term thereof), and, to the Knowledge of the Company, is valid and binding on the
other parties thereto, in each case, as enforceability may be limited by the Bankruptcy and Equity
Exceptions, (ii)&nbsp;each of the Company, its Subsidiaries and the Affiliated Medical Practices has
performed all material obligations required to be performed by it to date under each Company
Contract, and (iii)&nbsp;no event or condition exists which constitutes or, after notice or lapse of
time or both, would constitute a material default on the part of the Company, its Subsidiaries or
the Affiliated Medical Practices under any such Company Contract, except, in each case, with
respect to the foregoing clauses (i)&nbsp;through (iii)&nbsp;as would not reasonably be expected to result
in, either individually or in the aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.14 <U>Undisclosed Liabilities</U>. Except for (a)&nbsp;liabilities that are fully
reflected or reserved against on the consolidated balance sheet of the Company included in the
Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2010, (b)&nbsp;liabilities
incurred since March&nbsp;31, 2010 in the Ordinary Course of Business, (c)&nbsp;liabilities arising under the
terms of (but not from any breach or default under) any agreement, contract, commitment, license,
permit, lease or other instrument or obligation that is either (i)&nbsp;disclosed in the Company
Disclosure Schedule or (ii)&nbsp;not required to be so disclosed by the terms of this Agreement (and
including any of the foregoing types of instruments or obligations that are entered into or
obtained after the date of this Agreement, as long such action does not result in a breach of this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement), (d)&nbsp;liabilities incurred pursuant to or in connection with this Agreement or the
transactions contemplated hereby or (e)&nbsp;liabilities that would not reasonably be expected to result
in, individually or in the aggregate, a Company Material Adverse Effect, neither the Company, any
of its Subsidiaries nor any of the Affiliated Medical Practices has any liability of any nature
whatsoever (whether absolute, accrued or contingent or otherwise and whether due or to become due)
that would be required by GAAP to be reflected in the consolidated balance sheet of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.15 <U>Anti-Takeover Provisions</U>. To the Knowledge of the Company and subject to
the accuracy of Parent&#146;s and Merger Sub&#146;s representations and warranties contained in <U>Section
4.11</U> below, no Takeover Statute or similar statute or regulation applies or purports to apply
to the Company with respect to this Agreement, the Merger or any of the transactions contemplated
by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.16 <U>Company Information</U>. The information relating to the Company, its
Subsidiaries or the Affiliated Medical Practices to be included in the Proxy Statement will not
contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements therein, in light of the circumstances in which they are made, not misleading. The
Proxy Statement (except for such portions thereof that relate only to Parent, Merger Sub or any of
their respective Subsidiaries) will comply as to form in all material respects with the Exchange
Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.17 <U>Title to Property</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Real Property</U>. None of the Company, its Subsidiaries nor the Affiliated Medical
Practices owns, or has ever owned, any real property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Personal Property</U>. The Company, its Subsidiaries and the Affiliated Medical
Practices have good, valid and marketable title to all tangible personal property owned by it on
the date hereof, free and clear of all Liens other than Permitted Liens, except where the failure
to have such title would not reasonably be expected to result in, either individually or in the
aggregate, a Company Material Adverse Effect. With respect to personal property used in the
business of the Company, its Subsidiaries and the Affiliated Medical Practices which is leased
rather than owned, neither the Company nor any Subsidiary or Affiliated Medical Practice is in
default under the terms of any such lease the loss of which would reasonably be expected to result
in, either individually or in the aggregate, a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Leased Property</U>. All leases of real property and all other leases material to the
Company, its Subsidiaries and the Affiliated Medical Practices under which the Company, a
Subsidiary or Affiliated Medical Practice, as lessee, leases real or personal property are valid
and binding in accordance with their respective terms, there is not under such lease any material
existing default by the Company or such Subsidiary or Affiliated Medical Practice or, to the
Knowledge of the Company, the lessors thereunder, or any event which with notice or lapse of time
would constitute such a default, and in the case of real estate leases the Company or such
Subsidiary or Affiliated Medical Practice quietly enjoys the premises provided for in such lease
except, in each case, as would not reasonably be expected to result in, individually or in the
aggregate, a Company Material Adverse Effect.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used herein, &#147;<U>Permitted Liens</U>&#148; means (i)&nbsp;Liens publicly disclosed in the Company
SEC Reports filed prior to the date hereof, (ii)&nbsp;Liens disclosed in <U>Section&nbsp;3.17</U> of the
Company Disclosure Schedule, (iii)&nbsp;Liens for current Taxes not yet due and payable and other
standard exceptions commonly found in title policies in the jurisdiction where the property is
located, (iv)&nbsp;such encumbrances and imperfections of title, if any, as do not materially detract
from the value of the properties and do not materially interfere with the present or proposed use
of such properties or otherwise materially impair such operations, (v)&nbsp;Liens imposed or promulgated
by laws with respect to real property and improvements, including zoning regulations, (vi)
mechanics&#146;, carriers&#146;, workmen&#146;s, repairmen&#146;s and similar Liens incurred in the Ordinary Course of
Business or (vii)&nbsp;Liens that would not reasonably be expected to result in, individually or in the
aggregate, a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.18 <U>Insurance</U>. The Company, its Subsidiaries and the Affiliated Medical
Practices are insured with reputable insurers against such risks and in such amounts as the
management of the Company reasonably has determined to be prudent in accordance with industry
practice (taking into account the cost and availability of such insurance) except as would not
reasonably be expected to result in, individually or in the aggregate, a Company Material Adverse
Effect. The Company and each of its Subsidiaries and the Affiliated Medical Practices are in
compliance with its insurance policies and is not in default under any of the terms thereof, except
for any such non-compliance or default that would not reasonably be expected to result in a Company
Material Adverse Effect. Each such policy is outstanding and in full force and effect (other than
due to the ordinary expiration of the term thereof). All premiums and other payments due under any
such policy have been paid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.19 <U>Environmental Liability</U>. Except in each case as would not have a Company
Material Adverse Effect:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The operations of the Company, its Subsidiaries and the Affiliated Medical Practices are
in compliance with all applicable Environmental Laws, which compliance includes obtaining,
maintaining and complying with any Permits required under all applicable Environmental Laws
necessary to operate their respective businesses (&#147;<U>Environmental Permits</U>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company, its Subsidiaries and the Affiliated Medical Practices are not subject to any
pending, or to the Knowledge of the Company, threatened claim alleging that the Company, its
Subsidiaries or the Affiliated Medical Practices may be in violation of any Environmental Law or
any Environmental Permit or may have any liability under any Environmental Law; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There are no pending or, to the Knowledge of the Company, threatened investigations of the
businesses of the Company, its Subsidiaries or the Affiliated Medical Practices or any currently
or, to the Knowledge of the Company, previously owned or leased property of the Company, its
Subsidiaries or the Affiliated Medical Practices under Environmental Laws, which would reasonably
be expected to result in the Company, its Subsidiaries or the Affiliated Medical Practices
incurring any material liability pursuant to any Environmental Law.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.20 <U>Intellectual Property</U>. The Company, its Subsidiaries and the Affiliated
Medical Practices own, or have rights to use, all inventions, know-how, patents, patent
applications, trademarks, trademark applications, service marks, trade names, copyrights, domain
names, trade secrets and other similar rights that are used in the conduct of their respective
businesses as currently operated which the failure to so have would have or reasonably be expected
to result in a Company Material Adverse Effect (collectively, the &#147;<U>Intellectual Property
Rights</U>&#148;). <U>Section&nbsp;3.20</U> of the Company Disclosure Schedule sets forth a complete and
accurate list of the Company&#146;s, its Subsidiaries&#146; and the Affiliated Medical Practices&#146; material
Intellectual Property Rights. The Intellectual Property Rights have not expired or terminated, nor
are they expected to expire or terminate, within three (3)&nbsp;years from the date of this Agreement.
None of the Company, its Subsidiaries or the Affiliated Medical Practices has received written
notice that any Intellectual Property Right used by the Company, its Subsidiaries or the Affiliated
Medical Practices violates or infringes upon the rights of any third Person. To the Knowledge of
the Company, the Intellectual Property Rights do not infringe any patent, copyright, trademark,
trade name or other proprietary rights of any third Person, and there is no claim, action or
proceeding being made or brought against, or to the Knowledge of the Company, being threatened
against, the Company, any of its Subsidiaries or the Affiliated Medical Practices or any of the
Intellectual Property Rights. To the Knowledge of the Company, there is no infringement by another
Person of any of its Intellectual Property Rights and none of its Intellectual Property Rights are
unenforceable. The Company, its Subsidiaries and the Affiliated Medical Practices have taken
commercially reasonable security measures to protect the secrecy, confidentiality and value of all
of the Intellectual Property Rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.21 <U>Labor Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;None of the Company&#146;s or its Subsidiaries&#146; employees is covered by a collective bargaining
agreement and, to the Knowledge of the Company, there is no union or other organization seeking or
claiming to represent any such employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There is no labor dispute, strike, work stoppage or lockout, or, to the Company&#146;s
Knowledge, threat thereof, by or with respect to any of the Company&#146;s or its Subsidiaries&#146;
employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company and its Subsidiaries have not engaged in any unfair labor practice, and to the
Knowledge of the Company, there is no pending or threatened labor board proceeding of any kind,
including any such proceeding against the Company or its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;No grievance or arbitration demand or proceeding has been filed, or to the Company&#146;s
Knowledge, is threatened against the Company or its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No citation has been issued by OSHA against the Company or its Subsidiaries and no notice
of contest, claim, complaint, charge, investigation or other administrative enforcement proceeding
involving the Company or its Subsidiaries has been filed or is pending or, to the Company&#146;s
Knowledge, threatened against the Company or its Subsidiaries under OSHA or any other applicable
Law relating to occupational safety and health.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Neither the Company nor any of its Subsidiaries has taken any action that would constitute
a &#147;mass layoff,&#148; &#147;mass termination&#148; or &#147;plant closing&#148; within the meaning of the United States
Worker Adjustment and Retraining Notification Act or otherwise trigger notice requirements or
liability under any federal, local, state or foreign plant closing notice or collective dismissal
Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;To the Company&#146;s Knowledge, the Company and its Subsidiaries are in material compliance
with all applicable laws, regulations and orders governing or concerning labor relations, union and
collective bargaining, conditions of employment, employment discrimination and harassment, wages,
hours or occupational safety and health, including, without limitation, ERISA, the Immigration
Reform and Control Act of 1986, the National Labor Relations Act, the Civil Rights Acts of 1866 and
1964, the Equal Pay Act, the Age Discrimination in Employment Act, the Americans with Disabilities
Act, the Family and Medical Leave Act, the Worker Adjustment and Retraining Notification Act, OSHA,
the Davis-Bacon Act, the Walsh-Healy Act, the Service Contract Act, Executive Order 11246, and the
Rehabilitation Act of 1973 and all regulations under such acts, except where such non-compliance
would not have a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.22 <U>Certain Business Practices</U>. None of the Company, its Subsidiaries, the
Affiliated Medical Practices or, to the Knowledge of the Company, any directors or officers, agents
or employees of the Company, its Subsidiaries or the Affiliated Medical Practices, has (a)&nbsp;used any
funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to
political activity; (b)&nbsp;made any unlawful payment to foreign or domestic government officials or
employees or to foreign or domestic political parties or campaigns or violated any provision of the
Foreign Corrupt Practices Act of 1977, as amended; or (c)&nbsp;made any payment in the nature of
criminal bribery.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.23 <U>Opinion of Financial Advisor</U>. Goldman Sachs &#038; Co. has delivered to the
Company Board its opinion to the effect that, as of the date of such opinion and subject to the
assumptions and qualifications set forth therein, the Merger Consideration to be received by the
Stockholders is fair, from a financial point of view, to such Stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3.24 <U>No Other Representations or Warranties</U>. Except for the representations
and warranties expressly contained in this <U>Article&nbsp;III</U> (as modified by the Company
Disclosure Schedule), neither the Company nor any other Person makes any other express or implied
representation or warranty with respect to the Company, the Company&#146;s Subsidiaries, the Affiliated
Medical Practices or the transactions contemplated by this Agreement, and the Company disclaims any
other representations or warranties, whether made by the Company or any of its Affiliates,
officers, directors, employees, agents or representatives. Except for the representations and
warranties expressly contained in this <U>Article&nbsp;III</U>, the Company hereby disclaims all
liability and responsibility for any representation, warranty, projection, forecast, statement, or
information made, communicated, or furnished (orally or in writing) to Parent, Merger Sub or any of
their Affiliates or representatives (including any opinion, information, projection, or advice that
may have been or may be provided to Parent by any director, officer, employee, agent, consultant,
or representative of the Company or any of its Affiliates).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV<BR>
REPRESENTATIONS AND WARRANTIES<BR>
OF PARENT AND MERGER SUB</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Merger Sub, jointly and severally, hereby represent and warrant as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.01 <U>Organization</U>. Each of Parent and Merger Sub is duly organized, validly
existing and in good standing under the laws of its jurisdiction of formation. Each of Parent and
Merger Sub has the power and authority to own or lease all of its properties and assets and to
carry on its business as it is now being conducted, and is duly licensed or qualified to do
business in each jurisdiction in which the nature of the business currently conducted by it or the
character or location of the properties and assets owned or leased by it makes such licensing or
qualification necessary, except where the failure to be so licensed or qualified would not
reasonably be expected to result in a Parent Material Adverse Effect. The copies of the formation
documents of Parent and Merger Sub which have previously been made available to the Company are
true, complete and correct copies of such documents as in effect as of the date of this Agreement.
As used in this Agreement, a &#147;<U>Parent Material Adverse Effect</U>&#148; means a material adverse
effect on the ability of Parent or Merger Sub to consummate the transactions contemplated by this
Agreement in a timely manner or otherwise prevent or materially delay Parent or Merger Sub from
performing any of its material obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.02 <U>Authority Relative to this Agreement</U>. Each of Parent and Merger Sub has
all requisite right and power and authority to enter into this Agreement and the documents and
instruments to be executed and delivered by it pursuant hereto, and to perform its obligations
hereunder and thereunder. The execution, delivery and performance by Parent or Merger Sub of this
Agreement and the documents and instruments to be executed and delivered by them pursuant hereto
have been duly authorized by all necessary corporate or limited liability company action, as
applicable. This Agreement and the documents and instruments to be executed and delivered pursuant
hereto by Parent or Merger Sub are and will be the legal, valid and binding obligations of Parent
and Merger Sub, respectively, enforceable against them in accordance with their terms, except as
enforcement may be limited by the Bankruptcy and Equity Exceptions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.03 <U>Consents and Approvals; No Violations</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except for applicable requirements of the HSR Act, and the filing of the Certificate of
Merger in accordance with the DGCL, no filing or registration with, and no permit, authorization,
consent or approval of, any Governmental Entity or third Person is necessary for (i)&nbsp;the execution
and delivery by Parent or Merger Sub of this Agreement and the adoption of this Agreement by
Parent, in its capacity as sole stockholder of Merger Sub or (ii)&nbsp;the consummation by Parent or
Merger Sub of the Merger and the other transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the execution and delivery of this Agreement or the documents and instruments to
be executed and delivered pursuant hereto by Parent or Merger Sub nor the consummation by Parent or
Merger Sub of the transactions contemplated hereby or thereby, nor
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">compliance by Parent or
Merger Sub with any of the provisions hereof or thereof, will (i)&nbsp;conflict with or result in any
breach of any provision of the respective organizational documents of Parent or Merger Sub, (ii)
assuming the filings, consents and approvals referred to in
<U>Section&nbsp;4.03(a)</U> are duly obtained or made (A)&nbsp;result in a violation or breach of, or
constitute (with or without due notice or lapse of time or both) a default or give rise to any
right of termination, cancellation or acceleration of or loss of a material benefit under, or
result in the creation of any Lien in or upon any of the properties or assets of Parent or Merger
Sub under, or require any consent, approval or notice under, any of the terms, conditions or
provisions of any note, bond, mortgage, indenture, license, contract, agreement, lease or other
instrument or obligation to which either Parent or Merger Sub is a party or (B)&nbsp;violate any order,
writ, injunction, decree, statute, rule or regulation applicable to Parent or Merger Sub or any of
their properties or assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.04 <U>Litigation</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;There is no legal action, suit, arbitration, or other legal or administrative proceeding
or investigation before any Governmental Entity pending or, to the Knowledge of Parent, threatened,
that questions the validity of this Agreement or any other documents or instruments to be executed
and delivered by Parent or Merger Sub pursuant hereto, or the right of Parent and Merger Sub to
enter into this Agreement or any such other documents or instruments, or to consummate the
transactions contemplated hereby or thereby. As used herein, &#147;<U>to the Knowledge of Parent</U>&#148;
shall mean the actual knowledge of the officers of Parent or Merger Sub.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There is no injunction, order, judgment, decree or regulatory restriction of any
Governmental Entity specifically imposed upon Parent, Merger Sub or any of their respective
Subsidiaries or the assets of Parent, Merger Sub or any of their respective Subsidiaries which has
resulted in or would reasonably be expected to result in, individually or in the aggregate, a
Parent Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.05 <U>Brokers, Finders and Investment Bankers</U>. Neither Parent nor Merger Sub
has employed any broker or finder or incurred any liability for any broker&#146;s fees, commissions or
finder&#146;s fees in connection with any of the transactions contemplated by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.06 <U>Parent Information</U>. The information relating to Parent and its
Subsidiaries (including Merger Sub) to be provided by Parent to be contained in the Proxy
Statement, any filing pursuant to Rule&nbsp;14a-12 or Rule&nbsp;14a-6 under the Exchange Act or in any other
document filed with any other Governmental Entity in connection herewith, will not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in light of the circumstances in which they are made, not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.07 <U>No Business Activities by Merger Sub</U>. All of the outstanding capital
stock of Merger Sub is owned by Parent. Other than this Agreement, the Voting Agreement and any
other agreement entered into in connection with the transactions contemplated hereby, Merger Sub is
not a party to any contract and has not conducted any activities other than in connection with the
organization of Merger Sub, the negotiation and execution of this Agreement and the consummation of
the transactions contemplated hereby. Merger Sub has no Subsidiaries.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.08 <U>Funds</U>. Immediately prior to the Effective Time, Parent will have
sufficient immediately available funds to enable Parent to pay in full the Aggregate Consideration
and all fees and expenses payable by Parent in connection with this Agreement and the transactions
contemplated hereby. Without limiting the generality of the foregoing, Parent&#146;s ability to
consummate the transactions contemplated hereby is not contingent on Parent&#146;s ability to complete
any public offering or private placement of equity or debt securities or to obtain any other type
of financing prior to or on the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.09 <U>Ownership of Company Common Stock; No Other Agreements</U>. Neither Parent,
Merger Sub nor any of their respective Subsidiaries or any of their respective Affiliates or
associates (as such term is defined under the Exchange Act) (a)&nbsp;beneficially owns, directly or
indirectly, or (b)&nbsp;is a party to any agreement, arrangement or understanding for the purpose of
acquiring, holding, voting or disposing of, in case of either clause (a)&nbsp;or (b), any Company Common
Stock, in each case, except in accordance with this Agreement, including the Merger, and the Voting
Agreement. Neither Parent, Merger Sub nor any of their respective Subsidiaries or any of their
respective Affiliates or associates (as such term is defined under the Exchange Act) has entered
into any contract or agreement with any officer or director of the Company in connection with the
transactions contemplated by this Agreement, except for the Voting Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.10 <U>No Vote Required</U>. No approval of the stockholders of Parent is required
to approve this Agreement, the Merger or the other transactions contemplated hereby, other than
those obtained prior to the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.11 <U>Solvency</U>. As of the Effective Time and immediately after giving effect
to all of the transactions contemplated by this Agreement, including the Merger and all payments
contemplated by this Agreement in connection with the Merger and payment of all related fees and
expenses of Parent, Merger Sub, the Company and their respective Subsidiaries in connection
therewith, and assuming (i)&nbsp;the accuracy as of the Effective Time in all material respects of the
representations and warranties of the Company set forth in <U>Article&nbsp;III</U> (ignoring all
Company Material Adverse Effect qualifiers) and (ii)&nbsp;any projections made available to Parent by
the Company have been prepared in good faith based upon reasonable assumptions: (a)&nbsp;the amount of
the &#147;fair saleable value&#148; of the assets of the Surviving Corporation and its Subsidiaries on a
consolidated basis will exceed (i)&nbsp;the value of all liabilities of the Surviving Corporation and
its Subsidiaries on a consolidated basis, and (ii)&nbsp;the amount that will be required to pay the
liabilities of the Surviving Corporation and its Subsidiaries on their existing debts as such debts
become absolute and matured, (b)&nbsp;the Surviving Corporation and its Subsidiaries on a consolidated
basis will not have an unreasonably small amount of capital for the operation of the businesses in
which they are engaged or proposed to be engaged, and (c)&nbsp;the Surviving Corporation and its
Subsidiaries on a consolidated basis will be able to pay their liabilities, as they mature. For
purposes of the foregoing, &#147;not have an unreasonably small amount of capital for the operation of
the businesses in which they are engaged or proposed to be engaged&#148; and &#147;able to pay their
liabilities, as they mature&#148; means that such Person will be able to generate enough cash from
operations, asset dispositions or refinancing, or a combination thereof, to meet its
obligations as they become due.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.12 <U>Section&nbsp;203 of the DGCL</U>. As of the date hereof, neither Parent nor
Merger Sub nor any of their respective &#147;affiliates&#148; or &#147;associates&#148; is, and at no time during the
last three (3)&nbsp;years has been, an &#147;interested stockholder&#148; of the Company, as such terms are
defined in Section&nbsp;203 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4.13 <U>Acknowledgement of Parent</U>. Parent acknowledges and agrees that it has
conducted its own independent review and analysis of the business, assets, condition and operations
of the Company, its Subsidiaries and the Affiliated Medical Practices. In entering into this
Agreement, Parent has relied solely upon its own investigation and analysis and the representations
and warranties, covenants and agreements of the Company contained in this Agreement and Parent
(a)&nbsp;acknowledges that, other than as set forth in this Agreement, none of the Company nor any of
its directors, officers, employees, Affiliates, agents or representatives makes or has made any
representation or warranty, either express or implied, as to the accuracy or completeness of any of
the information provided or made available to Parent or its agents or representatives prior to the
execution of this Agreement (including, without limitation, any projected financial statements,
cash flow projections and other forward-looking data of the Company, its Subsidiaries and the
Affiliated Medical Practices and certain business plan information of the Company, its Subsidiaries
and the Affiliated Medical Practices), (b)&nbsp;agrees, to the fullest extent permitted by Law, that
none of the Company nor any of its directors, officers, employees, Affiliates, agents or
representatives shall have any liability or responsibility whatsoever to Parent on any basis
(including in contract, tort or otherwise) based upon any information provided or made available,
or statements made, to Parent prior to the execution of this Agreement, and (c)&nbsp;acknowledges that
it is not aware of any representation or warranty of the Company set forth in Article&nbsp;III of this
Agreement being untrue or inaccurate.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V<BR>
COVENANTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.01 <U>Access to Information</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Prior to the Closing Date, upon reasonable notice to the Company (and, with respect to
sensitive information of the Company, its Subsidiaries and the Affiliated Medical Practices with
respect to their respective operations or business opportunities directly competitive with Parent
or any of Parent&#146;s Subsidiaries, upon the consent of the Company, not to be unreasonably withheld),
Parent shall be entitled, through its officers, employees and representatives (including its legal
advisors and accountants), to make such investigation of the properties, businesses and operations
of the Company, its Subsidiaries and the Affiliated Medical Practices and such examination of the
books and records of the Company, its Subsidiaries and the Affiliated Medical Practices as it
reasonably requests and, at Parent&#146;s cost and expense, to make extracts and copies of such books
and records. Any such investigation and examination shall be conducted during regular business
hours and under reasonable circumstances and shall be subject to restrictions under applicable Law.
The Company shall cause the officers, employees, consultants, agents, accountants, attorneys and
other representatives of the Company, its Subsidiaries and the Affiliated Medical Practices to
cooperate with Parent and Parent&#146;s
representatives in connection with such investigation and examination, and Parent and its
representatives shall cooperate with the Company, its Subsidiaries and the Affiliated Medical
Practices and their respective representatives and shall use their reasonable efforts to minimize
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any disruption to the businesses of the Company, its Subsidiaries and the Affiliated Medical
Practices. Notwithstanding the foregoing, neither the Company nor any of its Subsidiaries or the
Affiliated Medical Practices shall be required to provide access to or to disclose information
where such access or disclosure would (i)&nbsp;violate or prejudice the rights of its customers,
(ii)&nbsp;waive the attorney-client privilege of the institution in possession or control of such
information, (iii)&nbsp;contravene any Law, rule, regulation, order, judgment, decree, fiduciary duty or
binding agreement entered into prior to the date of this Agreement in the Ordinary Course of
Business or (iv)&nbsp;be adverse to the interests of the Company, any of its Subsidiaries or any of the
Affiliated Medical Practices in any pending or threatened litigation between the parties hereto
over the terms of this Agreement; provided that for purposes of clauses (i), (ii)&nbsp;and (iii)&nbsp;above,
the Company has used its commercially reasonable efforts to provide the requested information in a
way that would not result in such violation, waiver or contravention, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All information and materials furnished pursuant to this Agreement shall be subject to the
provisions of the Confidentiality Agreement, dated February&nbsp;10, 2010, between Parent and the
Company (the &#147;<U>Confidentiality Agreement</U>&#148;). The Company makes no representation or warranty
as to the accuracy of any information provided pursuant to <U>Section&nbsp;5.01(a)</U>, and neither
Parent nor Merger Sub may rely on the accuracy of any such information, in each case other than as
expressly set forth in the Company&#146;s representations and warranties contained in <U>Article
III</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.02 <U>Conduct of Business</U>. Except as set forth in <U>Section&nbsp;5.02</U> of the
Company Disclosure Schedule or as permitted under <U>Section&nbsp;5.03</U> of the Company Disclosure
Schedule or <U>Section&nbsp;9.15</U> of the Company Disclosure Schedule, from the date hereof until the
Closing, the Company, its Subsidiaries and the Affiliated Medical Practices shall conduct their
respective businesses in accordance with past practice and in the Ordinary Course of Business,
maintain the current business organization and goodwill, use all commercially reasonable efforts to
continue to retain the services of the Company&#146;s, its Subsidiaries&#146; and the Affiliated Medical
Practices&#146; present officers, employees, consultants, and independent contractors and preserve the
Company&#146;s, its Subsidiaries&#146; and the Affiliated Medical Practices&#146; goodwill and relationship with
vendors, suppliers, dealers, distributors, customers and others having business dealings with the
Company, its Subsidiaries and the Affiliated Medical Practices, and the Company, its Subsidiaries
and the Affiliated Medical Practices shall not enter into any transaction or perform any act which
would constitute a breach of its representations, warranties, covenants and agreements contained
herein. The Company shall notify Parent promptly, but in all cases within three (3)&nbsp;Business Days
after the Company gains Knowledge, of (a)&nbsp;any event or circumstance which is reasonably likely to
have a Company Material Adverse Effect; (b)&nbsp;any material change in the normal course of business or
in the operation of the assets of the Company, any of its Subsidiaries or any of the Affiliated
Medical Practices, (c)&nbsp;the resignation or written notice of resignation or termination of any
officer of the Company, any of its Subsidiaries or any of the Affiliated Medical Practices, or (d)
any material governmental complaints, investigations or hearings (or communications indicating that
the same may be contemplated) or any adjudicatory proceedings, directed at or involving the
Company, any of its Subsidiaries or any of the Affiliated Medical Practices or their
respective employees or independent contractors in their capacities as such.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.03 <U>Certain Changes or Events</U>. From the date hereof until the Closing,
except with the prior written consent of Parent (such consent not to be unreasonably withheld,
delayed or conditioned) or except as set forth on <U>Section&nbsp;5.03</U> of the Company Disclosure
Schedule, the Company shall not, and shall cause its Subsidiaries and the Affiliated Medical
Practices not to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;take any action to amend its certificate of incorporation or bylaws or other governing
instruments;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;issue, sell or otherwise dispose of any of its authorized but unissued capital stock other
than in connection with the exercise of a Company Option, or issue any option to acquire its
capital stock, or any securities convertible into or exchangeable for its capital stock or split,
combine or reclassify any shares of its capital stock, or create any phantom stock, stock
appreciation rights plan or similar plan;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;declare or pay any dividend or make any other distribution in cash or property on any
capital stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;merge or consolidate with or into any Person;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;sell or otherwise dispose of or encumber any of its properties or assets other than in
sales or dispositions in the Ordinary Course of Business or in connection with normal repairs,
renewals and replacements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;create any subsidiary, acquire any capital stock or other equity securities of any third
party or acquire any equity or ownership interest in any business or entity, except as set forth on
<U>Schedule&nbsp;9.15(a)</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) (i)&nbsp;create, incur or assume any Indebtedness for borrowed money or secured by real or
personal property, except for trade payables incurred in the Ordinary Course of Business, (ii)
grant or incur any Liens on any real or personal property that did not exist on the date hereof
except in the Ordinary Course of Business, (iii)&nbsp;incur any liability or obligation (absolute,
accrued or contingent) not covered by clause (i)&nbsp;except in the Ordinary Course of Business, (iv)
write-off any guaranteed checks, notes or accounts receivable except in the Ordinary Course of
Business, (v)&nbsp;write-down the value of any asset or investment on its books or records, except for
depreciation and amortization in the Ordinary Course of Business, (vi)&nbsp;make any commitment for any
capital expenditure in excess of $500,000 in the case of any single expenditure or $1,500,000 in
the case of all capital expenditures except with respect to any capitalized internal software
development, (vii)&nbsp;enter into any contract or agreement, except those that are (x)&nbsp;entered into in
the Ordinary Course of Business and involve an expenditure of less than $100,000 for any such
contract or agreement (exclusive of any indemnification obligations under such contract or
agreement for which no claims have been asserted as of the date thereof), or (y)&nbsp;cancelable without
premium or penalty on not more than thirty (30)&nbsp;days&#146; notice, or (viii)&nbsp;enter into any contract,
agreement or commitment related to a radiology practice
alliance, strategic partnership or similar corporate development program, except in as set
forth on <U>Schedule&nbsp;9.15(a)</U>;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) (i)&nbsp;increase in any manner the compensation of (including bonus), or fringe benefits of,
or enter into any new, or modify any existing, bonus, severance or incentive agreement or
arrangement with, any of its current or former officers, directors, management-level employees or
independent contractors, or (ii)&nbsp;hire or fire any officers;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;establish, adopt, enter into, materially amend, or terminate any Company Benefit Plan or
any plan, arrangement, program, policy, trust, fund or other arrangement that would constitute a
Company Benefit Plan if it were in existence as of the date of this Agreement, except as required
by Law or increase the benefits provided under any Company Benefit Plan, or promise or commit to
undertake any of the foregoing in the future;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;fail to perform its material obligations under, or default or suffer to exist any event or
condition which with notice or lapse of time or both would constitute a material default under, any
Company Contract (except those being contested in good faith) or enter into, assume or amend any
contract or commitment that is or would be a Company Contract, except in the Ordinary Course of
Business or as permitted under <U>Section&nbsp;5.03</U> of the Company Disclosure Schedule or
<U>Section&nbsp;9.15</U> of the Company Disclosure Schedule;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;fail to maintain in full force and effect policies of insurance comparable in amount and
scope to those it currently maintains;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;make or change any material Tax election, settle or compromise any material Tax claim or
assessment, change an annual Tax accounting period, adopt or change any material Tax accounting
method, file any material amended Tax Return, waive or extend the limitation period applicable to
any material Tax liability or assessment (other than pursuant to extensions or time to file Tax
returns obtained in the Ordinary Course of Business), enter into any closing agreement with
respect to a material amount of Taxes or surrender any right to claim a refund of a material amount
of Taxes; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;enter into any contract, agreement or commitment with respect to, or propose or authorize,
any of the actions described in the foregoing clauses (a)&nbsp;through (l).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.04 <U>No Control of Company&#146;s Business</U>. Nothing contained in this Agreement is
intended to give Parent or Merger Sub, directly or indirectly, the right to control or direct the
Company&#146;s, its Subsidiaries&#146; or the Affiliated Medical Practices&#146; operations prior to the Effective
Time. Prior to the Effective Time, the Company, its Subsidiaries and the Affiliated Medical
Practices shall exercise, consistent with the terms and conditions of this Agreement, complete
control and supervision over their respective businesses, assets and operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.05 <U>Proxy Statement; Other Filings</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As promptly as practicable following the date of this Agreement (and in any event within
15&nbsp;days), (a)&nbsp;the Company shall prepare and file with the SEC a preliminary
form of the Proxy Statement or Information Statement, as applicable, and (b)&nbsp;each of the
Company and Parent shall, or shall cause their respective Affiliates to, prepare and file with the
SEC any other filings that are required to be filed by such party with the SEC (&#147;<U>Other
Filings</U>&#148;) in connection with the transactions contemplated hereby. Each of the Company and
Parent shall furnish all information concerning itself and its Affiliates, and with respect to the
Company, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Affiliated Medical Practices, that is required to be included in the Proxy Statement
or Information Statement, as applicable, or, to the extent applicable, the Other Filings, or that
is customarily included in proxy statements or information statements, as applicable, or other
filings prepared in connection with transactions of the type contemplated by this Agreement. Each
of the Company and Parent shall use its commercially reasonable efforts to respond as promptly as
practicable to any comments of the SEC with respect to the Proxy Statement or Information
Statement, as applicable, or the Other Filings, and the Company shall use its commercially
reasonable efforts to cause the definitive Proxy Statement or Information Statement, as applicable,
to be mailed to the Stockholders as promptly as reasonably practicable after the date of this
Agreement. Each party shall promptly notify the other parties upon the receipt of any comments
from the SEC or its staff or any request from the SEC or its staff for amendments or supplements to
the Proxy Statement or Information Statement, as applicable, or the Other Filings and shall provide
the other party with copies of all correspondence between it and its representatives, on the one
hand, and the SEC and its staff, on the other hand relating to the Proxy Statement or Information
Statement, as applicable, or the Other Filings. If at any time prior to the Company Stockholder
Meeting, any information relating to the Company, its Subsidiaries, the Affiliated Medical
Practices, Merger Sub, Parent or any of their respective Affiliates, officers or directors, should
be discovered by the Company or Parent which should be set forth in an amendment or supplement to
the Proxy Statement or Information Statement, as applicable, or the Other Filings, so that the
Proxy Statement or Information Statement, as applicable, or the Other Filings shall not contain any
untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under
which they are made, not misleading, the party which discovers such information shall promptly
notify the other parties, and an appropriate amendment or supplement describing such information
shall be filed with the SEC and, to the extent required by applicable Law, disseminated to the
Stockholders. Notwithstanding anything to the contrary stated above, prior to filing or mailing
the Proxy Statement or Information Statement, as applicable, or filing the Other Filings (or, in
each case, any amendment or supplement thereto) or responding to any comments of the SEC with
respect thereto, the party responsible for filing or mailing such document shall provide the other
party a reasonable opportunity to review and comment on such document or response.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Subject to the other provisions of this Agreement, the parties hereto shall cooperate with
each other and use commercially reasonable efforts to promptly prepare and file all necessary
documentation, to effect all applications, notices, petitions and filings, to obtain as promptly as
practicable all material permits, consents, approvals and authorizations of all third parties and
Governmental Entities which are necessary or advisable to consummate the transactions contemplated
by this Agreement (including the Merger) and to comply with the terms and conditions of all such
permits, consents, approvals and authorizations of all such third parties and Governmental
Entities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Parent and the Company shall, upon request, furnish each other with all information
concerning themselves, their Subsidiaries, the Affiliated Medical Practices (with respect to the
Company), directors, officers and stockholders and such other matters as may be reasonably
necessary or advisable in connection with a statement, filing, notice or application made by or on
behalf of Parent, its Subsidiaries or the Company to any Governmental Entity in connection with the
Merger and the other transactions contemplated by this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Nothing in this <U>Section&nbsp;5.05</U> shall be deemed to prevent the Company or the Company
Board from taking any action they are permitted or required to take under, and in compliance with,
<U>Section&nbsp;5.10</U> or are required to take under applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.06 <U>Stockholder Approval</U>. Subject to the other provisions of this
Agreement, the Company shall take all necessary action in accordance with the DGCL and the
Certificate of Incorporation and Bylaws of the Company to duly call, give notice of, convene and
hold a special meeting of the Stockholders (the &#147;<U>Company Stockholder Meeting</U>&#148;), as promptly
as reasonably practicable after the mailing of the Proxy Statement, for the purpose of voting upon
the adoption of this Agreement. Subject to <U>Section&nbsp;5.10</U>, the Company Board shall recommend
to the Stockholders that they adopt this Agreement (the &#147;<U>Company Recommendation</U>&#148;) and shall
include the Company Recommendation in the Proxy Statement. Subject to <U>Section&nbsp;5.10</U>, the
Company will use commercially reasonable efforts to solicit from the Stockholders proxies in favor
of the adoption of this Agreement and will take all other action reasonably necessary or advisable
to secure the vote or consent of the Stockholders required by the rules of the Nasdaq Stock Market
or applicable Law to obtain such adoption. Notwithstanding the foregoing, the Company shall use
its commercially reasonable efforts to obtain a written consent constituting the Company Required
Vote as promptly as possible after the date hereof in accordance with the DGCL and the Certificate
of Incorporation and Bylaws of the Company to adopt this Agreement, in lieu of holding the Company
Stockholder Meeting; provided that such efforts shall not affect the covenant with respect to the
Company Stockholder Meeting set forth in the first sentence of this <U>Section&nbsp;5.06</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.07 <U>Further Actions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to the terms and conditions of this Agreement, each of Parent, Merger Sub and the
Company shall, and shall cause their respective Subsidiaries and the Affiliated Medical Practices
(with respect to the Company) to, use their commercially reasonable efforts (i)&nbsp;to take, or cause
to be taken, all actions necessary, proper or advisable to comply promptly with all legal
requirements which may be imposed on such party or its Subsidiaries with respect to the Merger and,
subject to the conditions set forth in <U>Article&nbsp;VI</U> hereof, to consummate the transactions
contemplated by this Agreement and (ii)&nbsp;to obtain (and to cooperate with the other party to obtain)
any consent, authorization, order or approval of, or any exemption by, any Governmental Entity and
any other third Person which is required to be obtained by the Company, Merger Sub or Parent or any
of their respective Subsidiaries or the Affiliated Medical Practices (with respect to the Company)
in connection with the Merger and the other transactions contemplated by this Agreement. Without
limiting the generality of the foregoing, each party shall, within five (5)&nbsp;Business Days after the
execution of this Agreement, file all necessary
documentation required to obtain all requisite approvals or termination of applicable waiting
periods for the transactions contemplated hereby under the HSR Act. Parent will bear the expenses
and costs incurred by the parties hereto in connection with any HSR Act filings or other such
competition filings and submissions which may be required by such party for the consummation of the
Merger pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding any other provision of this Agreement to the contrary, Parent agrees to
take any and all steps necessary to avoid or eliminate each and every impediment under any
antitrust or competition Law that may be asserted by any Governmental
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Entity or any other third
Person so as to enable the parties hereto to consummate the Merger as soon as practicable,
including committing to and/or effecting, by consent decree, hold separate orders, or otherwise,
the sale or disposition of such of the shares of Company Common Stock, or its or the Company&#146;s or
their respective Subsidiaries&#146; assets, as are required to be divested or entering into such other
arrangements as are required in order to avoid the entry of, or to effect the dissolution of, any
injunction, temporary restraining order or other order in any suit or proceeding, which would
otherwise have the effect of preventing or materially delaying the consummation of the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Nothing in this <U>Section&nbsp;5.07</U> shall be deemed to prevent the Company or the Company
Board from taking any action they are permitted or required to take under, and in compliance with,
<U>Section&nbsp;5.10</U> or are required to take under applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.08 <U>Employees; Employee Benefit Plans</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Parent shall, or shall cause the Surviving Corporation and its Subsidiaries to, (i)&nbsp;give
those employees who are, as of the Effective Time, employed by the Company and its Subsidiaries
(the &#147;<U>Continuing Employees</U>&#148;) full credit for purposes of eligibility, vesting and benefit
accruals under any employee benefit plans or arrangements maintained by Parent, the Surviving
Corporation or any Subsidiary of Parent or the Surviving Corporation (collectively, the &#147;<U>Parent
Plans</U>&#148;) for such Continuing Employees&#146; service with the Company or any of its Subsidiaries (or
any predecessor entity) to the same extent recognized by the Company and its Subsidiaries; (ii)
waive all limitations as to preexisting conditions, exclusions and waiting periods with respect to
participation and coverage requirements applicable to the Continuing Employees under any Parent
Plan that is a welfare benefit plan that such employees may be eligible to participate in after the
Effective Time; (iii)&nbsp;provide credit under any such welfare plan for any co-payments, deductibles
and out-of-pocket expenditures for the remainder of the coverage period during which any transfer
of coverage occurs; <U>provided</U>, <U>however</U>, that no such service shall be recognized to
the extent such recognition would result in the duplication of benefits; and (iv)&nbsp;honor, for a
period of no less than one year following the Effective Time, in accordance with their terms all
employee benefit plans or arrangements maintained by the Company immediately prior to the Effective
Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;From and after the Effective Time until the one year anniversary of the Effective Time,
and subject to the immediately following sentence, Parent shall, or shall cause the Surviving
Corporation and its Subsidiaries to, provide to the Continuing Employees compensation and benefit
arrangements that are no less favorable in the aggregate than the compensation and benefit
arrangements that are provided to similarly situated employees of
Parent; <U>provided</U>, <U>however</U>, that in no event shall such Continuing Employees&#146;
compensation and benefit arrangements be less favorable in the aggregate than such Continuing
Employees&#146; current compensation and benefit arrangements. As soon as practicable after the
Effective Time, Parent shall, or shall cause the Surviving Corporation and its Subsidiaries to,
cause the Continuing Employees to commence participation in such Parent Plans as are provided to
similarly situated employees of Parent. From and after the Effective Time until the one year
anniversary of the Effective Time and unless otherwise mutually agreed to by the parties in
writing, Parent and the Surviving Corporation shall keep in full force and effect, and comply with
the terms and conditions of, any agreement in effect as of the date of this Agreement between or
among the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company or any of its Subsidiaries and any of its or their employees relating to
severance pay or similar benefits.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The provisions of this <U>Section&nbsp;5.08</U> are for the sole benefit of the parties to
this Agreement and nothing herein, expressed or implied, is intended or shall be construed to
confer upon or give to any Person (including for the avoidance of doubt any Continuing Employees,
present or former employees or directors, consultants or independent contractors of the Company or
any of its Subsidiaries, Parent or any of its Subsidiaries, or on or after the Effective Time, the
Surviving Corporation or any of its Subsidiaries), other than the parties hereto and their
respective permitted successors and assigns, any legal or equitable or other rights or remedies
(with respect to the matters provided for in this <U>Section&nbsp;5.08</U>) under or by reason of any
provision of this Agreement. Nothing contained in this <U>Section&nbsp;5.08</U> or elsewhere in the
Agreement shall be construed to prevent, from and after the Effective Time, the termination of
employment of any individual Continuing Employee or, subject to the provisions of <U>Section
5.08(a)</U>, any change in the employee benefits available to any Continuing Employee or the
amendment or termination of any particular Plan in accordance with its terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.09 <U>Indemnification; Directors&#146; and Officers&#146; Insurance</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From and after the Effective Time, each of Parent and the Surviving Corporation shall
jointly and severally: (i)&nbsp;indemnify and hold harmless each individual who served as a director
and/or officer of the Company or any of its Subsidiaries prior to the Effective Time (collectively,
the &#147;<U>Indemnified Parties</U>&#148;) to the fullest extent authorized or permitted by Delaware law,
as now or hereafter in effect, in connection with any Claim and any judgments, fines (including
excise taxes), penalties and amounts paid in settlement (including all interest, assessments and
other charges paid or payable in connection with or in respect of such judgments, fines, penalties
or amounts paid in settlement) resulting therefrom; and (ii)&nbsp;promptly pay on behalf of or, within
thirty (30)&nbsp;days after any request for advancement, advance to each of the Indemnified Parties, to
the fullest extent authorized or permitted by Delaware law, as now or hereafter in effect, any
Expenses incurred in defending, serving as a witness with respect to or otherwise participating in
any Claim in advance of the final disposition of such Claim, including payment on behalf of or
advancement to the Indemnified Party of any Expenses incurred by such Indemnified Party in
connection with enforcing any rights with respect to such indemnification and/or advancement, in
each case without the requirement of any bond or other security, but in the case of advancement of
Expenses upon receipt of an undertaking, to the extent required by applicable Law, from such
Indemnified Party to repay such advanced Expenses if it is determined by a court of competent
jurisdiction in a final order that such Indemnified Party was not entitled to indemnification
hereunder with respect to such Expenses. In the event any Claim is brought against any
Indemnified Party, Parent and the Surviving Corporation shall each use all commercially reasonable
efforts to assist in the vigorous defense of such matter, provided that neither Parent nor the
Surviving Corporation shall settle, compromise or consent to the entry of any judgment in any Claim
(and in which indemnification could be sought by such Indemnified Party hereunder) without the
prior written consent of such Indemnified Party if and to the extent the claimant seeks any
non-monetary relief from such Indemnified Party, which consent will not be unreasonably withheld.
The indemnification and advancement obligations of Parent and the Surviving Corporation pursuant to
this <U>Section&nbsp;5.09(a)</U> shall extend to acts or omissions occurring at or before the Effective
Time and any Claim relating thereto (including with respect
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to any acts or omissions occurring in
connection with the approval of this Agreement and the consummation of the transactions
contemplated hereby and any Claim relating thereto) and all rights to indemnification and
advancement conferred hereunder shall continue as to an individual who has ceased to be a director
or officer of the Company or its Subsidiaries prior to the Effective Time and shall inure to the
benefit of such individual&#146;s heirs, executors and personal and legal representatives. In
connection with any determination as to whether the Indemnified Parties are entitled to the
benefits of this <U>Section&nbsp;5.09</U>, the burden of proof shall be on Parent and the Surviving
Corporation to establish that an Indemnified Party is not so entitled. As used in this
<U>Section&nbsp;5.09(a)</U>, (i)&nbsp;the term &#147;<U>Claim</U>&#148; means any threatened, asserted, pending or
completed action, suit or proceeding, or any inquiry or investigation, whether instituted by the
Company, any Governmental Entity or any other party, that any Indemnified Party in good faith
believes might lead to the institution of any such action, suit or proceeding, whether civil,
criminal, administrative, investigative or other, including any arbitration or other alternative
dispute resolution mechanism, arising out of or pertaining to matters that relate to such
Indemnified Party&#146;s duties or service as a director, officer, trustee, employee, agent, or
fiduciary of the Company, any of its Subsidiaries, any employee benefit plan maintained by any of
the foregoing at or prior to the Effective Time and any other Person at the request of the Company
or any of its Subsidiaries; and (ii)&nbsp;the term &#147;<U>Expenses</U>&#148; means attorneys&#146; fees and all
other costs, expenses and obligations (including experts&#146; fees, travel expenses, court costs,
retainers, transcript fees, duplicating, printing and binding costs, as well as telecommunications,
postage and courier charges) paid or incurred in connection with investigating, defending, being a
witness in or participating in (including on appeal), or preparing to investigate, defend, be a
witness in or participate in, any Claim for which indemnification is authorized pursuant to this
<U>Section&nbsp;5.09(a)</U>, including any action relating to a claim for indemnification or
advancement brought by an Indemnified Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Without limiting any of the obligations under paragraph (a)&nbsp;of this <U>Section&nbsp;5.09</U>,
from and after the Effective Time, Parent and the Surviving Corporation shall keep in full force
and effect, and comply with the terms and conditions of, any agreement in effect as of the date of
this Agreement between or among the Company or any of its Subsidiaries and any Indemnified Party
providing for the indemnification of such Indemnified Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Without limiting any of the obligations under paragraph (a)&nbsp;of this <U>Section&nbsp;5.09</U>,
Parent agrees that all rights to indemnification and all limitations of liability existing in favor
of the Indemnified Parties as provided in the Company&#146;s certificate of incorporation or bylaws or
in the corresponding documents of any of the Company&#146;s Subsidiaries as in effect as of the date of
this Agreement with respect to matters occurring on or
prior to the Effective Time shall survive the Merger and shall continue in full force and
effect thereafter, without any amendment thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If Parent or the Surviving Corporation or any of its successors or assigns shall (i)
consolidate with or merge into any other Person and shall not be the continuing or surviving Person
of such consolidation or merger or (ii)&nbsp;transfer all or substantially all of its properties and
assets to any Person, then, in each such case, proper provisions shall be made so that the
successors and assigns of Parent and the Surviving Corporation, as the case may be (including
Parent&#146;s ultimate parent entity, if applicable), assume all of the obligations of Parent and the
Surviving Corporation set forth in this <U>Section&nbsp;5.09</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;As of the Effective Time, Parent, the Surviving Corporation or the Company (with the
election being at Parent&#146;s option) shall have purchased and shall maintain in full force and effect
for a period of six (6)&nbsp;years after the Closing Date (or, if any Claim is asserted or made within
such six-year period, Parent shall ensure that such insurance remains in effect until final
disposition of such Claim) a prepaid directors&#146; and officers&#146; liability insurance policy or
policies providing each individual currently covered by the Company&#146;s directors&#146; and officers&#146;
liability insurance coverage for events occurring at or prior to the Effective Time (including acts
or omissions relating to the approval of this Agreement and consummation of the transactions
contemplated hereby) that is no less favorable than the Company&#146;s existing policy;
<U>provided</U>, <U>however</U>, that Parent may substitute therefor policies of at least the
same coverage and amounts containing terms and conditions which are in the aggregate no less
advantageous to such directors and officers of the Company than the terms and conditions of the
existing directors&#146; and officers&#146; liability insurance policy of the Company from reputable carriers
having a rating comparable to the Company&#146;s current carrier.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The provisions of this <U>Section&nbsp;5.09</U> shall survive the consummation of the Merger
and (i)&nbsp;are intended to be for the benefit of, and shall be enforceable by, each Indemnified Party
and his or her heirs and representatives and (ii)&nbsp;are in addition to, and not in substitution for,
any other rights to indemnification or contribution that any such Person may have by contract or
otherwise. The obligations of Parent or the Surviving Corporation under this <U>Section&nbsp;5.09</U>
shall not be terminated or modified in such a manner as to adversely affect the rights of any
Indemnified Party under this <U>Section&nbsp;5.09</U> without the consent of such affected Indemnified
Party. Parent shall cause the Surviving Corporation to perform all of the obligations of the
Surviving Corporation under this <U>Section&nbsp;5.09</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.10 <U>No Solicitation</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall, and shall cause each of its Subsidiaries, and shall cause their
respective officers, directors, representatives and agents (including any investment banker,
attorney or accountant retained by it or any of its Subsidiaries) (collectively, &#147;<U>Company
Representatives</U>&#148;) to, (i)&nbsp;immediately cease any existing discussions or negotiations, if any,
with any third Person that may be ongoing with respect to any actual or potential Acquisition
Proposal and (ii)&nbsp;with respect to parties with whom discussions have been terminated, the Company
shall use its reasonable best efforts to obtain the return or the destruction of, in accordance
with the terms of the applicable confidentiality agreement, confidential information previously
furnished by the Company, its Subsidiaries or Company
Representatives. The Company and its Subsidiaries shall not, and shall not authorize or
permit any Company Representative to, directly or indirectly, (i)&nbsp;solicit, initiate or knowingly
encourage an Acquisition Proposal, (ii)&nbsp;furnish or disclose to any third Person non-public
information with respect to an Acquisition Proposal, (iii)&nbsp;negotiate or engage in discussions with
any third Person with respect to an Acquisition Proposal (other than to advise such Person of the
Company&#146;s obligations under this <U>Section&nbsp;5.10</U>) or (iv)&nbsp;enter into any agreement (whether or
not binding) or agreement in principle with respect to, or approve or recommend, an Acquisition
Proposal; <U>provided</U>, <U>however</U>, that at any time prior to obtaining approval of the
Merger by the Company Required Vote (but not thereafter), in response to a bona fide written
Acquisition Proposal that was not solicited by the Company or any of its Representatives and which
the Company Board determines in good faith, after consulting with its financial advisors and
outside legal counsel, constitutes, or could reasonably
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be expected to lead to, a Superior
Proposal, the Company may (A)&nbsp;furnish information with respect to the Company, its Subsidiaries and
the Affiliated Medical Practices to the Person making such Acquisition Proposal (and its officers,
directors, employees, accountants, consultants, legal counsel, advisors, agents and other
representatives), and (B)&nbsp;participate in discussions or negotiations with, and provide draft
documents and agreements to, the Person making such Acquisition Proposal (and its officers,
directors, employees, accountants, consultants, legal counsel, advisors, agents and other
representatives) regarding such Acquisition Proposal, if (prior to furnishing such information to,
or entering into such discussions or negotiations with, such Person) the Company (1)&nbsp;provides
reasonable prior notice to Parent to the effect that it is furnishing information to, or entering
into discussions or negotiations with, such Person (but excluding the identity of such Person),
(2)&nbsp;provides Parent with all information to be provided to such Person which Parent has not
previously been provided, and (3)&nbsp;receives from such Person an executed confidentiality agreement
reasonably satisfactory to the Company Board and with terms substantially similar to and no less
favorable to the Company, in the aggregate, than those contained in the Confidentiality Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in this <U>Section&nbsp;5.10(b)</U>, neither the Company Board or any
committee thereof shall (i)&nbsp;withdraw, qualify, withhold or modify, or propose to withdraw, qualify,
withhold or modify, in a manner adverse to Parent, the Company Recommendation, (ii)&nbsp;approve or
recommend, or propose to approve or recommend, any Acquisition Proposal, (iii)&nbsp;enter into any
agreement (whether or not binding) or agreement in principle with respect to any Acquisition
Proposal (other than a confidentiality agreement referred to in <U>Section&nbsp;5.10(a)</U>) or (iv)
take any other action or make any recommendation or public statement in connection with a tender
offer or exchange offer other than a recommendation against such offer or otherwise take any action
inconsistent with the Company Recommendation. Notwithstanding the foregoing, if, at any time prior
to obtaining approval of the Merger by the Company Required Vote, the Company Board determines in
good faith after consultation with its outside legal counsel and financial advisors that the
failure to do so would violate its fiduciary duties to the Stockholders under applicable Law, then
the Company Board may withdraw, modify, or change in a manner adverse to Parent, the Company
Recommendation (a &#147;<U>Company Recommendation Change</U>&#148;); <U>provided</U>, <U>however</U>, that
if any such action is (A)&nbsp;not in response to a Superior Proposal, then a Company Recommendation
Change may only be made if directly related to an event, fact, circumstance, development or
occurrence that affects the assets or operations of the Company that is unknown to the Company
Board as of the date of this Agreement but becomes known to the Company Board prior to obtaining
approval of the Merger by the Company Required Vote or (B)&nbsp;in response to a Superior Proposal (that
was not solicited
in breach of this <U>Section&nbsp;5.10</U>) as determined by the Company Board in good faith after
consultation with outside counsel and its financial advisors, prior to making any Company
Recommendation Change or terminating this Agreement in accordance with <U>Section&nbsp;7.01(d</U>), the
Company shall, in all such cases, provide Parent with at least three (3)&nbsp;Business Days advance
written notice (such period, the <U>&#147;Notice Period&#148;</U>), advising Parent of its intention to make
a Company Recommendation Change or to terminate the Agreement to enter into a definitive agreement
with respect to a Superior Proposal, (ii)&nbsp;provide Parent in writing the material terms and
conditions of such Superior Proposal and a copy of the relevant proposed transaction documents with
the party making such Superior Proposal and other material documents (but excluding the identity of
such Person) and (iii)&nbsp;discuss with Parent, to the extent Parent wishes to discuss, any proposed
changes by Parent to the terms of this Agreement as to permit the Company not to effect a Company
Recommendation or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to terminate this Agreement in response to such a Superior Proposal and following
the Notice Period, and taking into account any revised proposal made by Parent since the
commencement of the Notice Period, determines in good faith after consultation with its outside
legal counsel and financial advisors that the Company Board is required to make a Company
Recommendation Change in the exercise of its fiduciary duties, and if it is in connection with a
Superior Proposal, the Superior Proposal remains a Superior Proposal. In the event of any material
change to the material terms of such Superior Proposal (any change in price shall be deemed a
material change of a material term), the Company Board shall deliver to Parent an additional notice
and shall comply with this <U>Section&nbsp;5.10(b</U>) with respect to such new notice, except that if
the only material change is a change in price, then the deadline for such new written notice shall
be 36 hours (rather than the three (3)&nbsp;Business Days otherwise contemplated by this <U>Section
5.10(b</U>)). None of the Company Board, any committee thereof or the Company shall enter into any
binding agreement with any Person to limit or not provide prior notice to Parent of its intent to
make a Company Recommendation Change or to terminate this Agreement in response to any Superior
Proposal.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Nothing contained in this Agreement shall prohibit the Company or the Company Board from
(i)&nbsp;taking and disclosing to the Stockholders a position contemplated by Rule&nbsp;14e-2 promulgated
under the Exchange Act or (ii)&nbsp;making any disclosure to the Stockholders if the Company Board
determines in good faith, after consultation with outside legal counsel, that such disclosure is
required by applicable securities law; provided, that, any such disclosure (other than a &#147;stop,
look and listen&#148; letter or similar communication of the type contemplated by Rule&nbsp;14d-9(f) under
the Exchange Act) shall be deemed a Company Recommendation Change.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;As used in this Agreement:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) &#147;<U>Acquisition Proposal</U>&#148; means any inquiry, proposal or offer (including any
proposal from or to the Stockholders from any person or &#147;group&#148; (as defined in <U>Section
13(d</U>) of the Exchange Act) other than Parent or its Affiliates) relating to (A)&nbsp;the acquisition, in any single transaction or series of related transactions, of more than twenty-five percent
(25%) of the outstanding shares of capital stock or any other voting securities of the Company by
any Person or group of Persons, (B)&nbsp;a merger, consolidation, business combination, reorganization,
share exchange, sale of assets, recapitalization, liquidation, dissolution or similar transaction
which would result in any Person acquiring twenty-five percent (25%) or more of the fair market
value of the assets of the Company and its
Subsidiaries, taken as a whole (including capital stock of Subsidiaries of the Company) by any
Person or group of Persons, (C)&nbsp;any other transaction which would result in a Person or group of
Persons acquiring twenty-five percent (25%) or more of the fair market value of the assets of the
Company and its Subsidiaries, taken as a whole (including capital stock of Subsidiaries of the
Company), immediately prior to such transaction (whether by purchase of assets, acquisition of
stock of a Subsidiary or otherwise) or (D)&nbsp;any combination of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) &#147;<U>Superior Proposal</U>&#148; means an Acquisition Proposal (with all of the percentages
included in the definition of Acquisition Proposal increased to fifty percent (50%)) on terms which
the Company Board determines in good faith (after consultation with its financial advisors and
outside legal counsel and consideration of all terms and conditions of such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Acquisition Proposal,
including the conditionality and the timing and likelihood of consummation of such Acquisition
Proposal) to be more favorable to the holders of Company Common Stock, including from a financial
point of view, than those set forth in this Agreement or the terms of any other proposal or revised
proposal made by Parent pursuant to the provisions of <U>Section&nbsp;5.10(b)</U> above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.11 <U>Standstill</U>. Until the earlier of the Effective Time or the termination
of this Agreement, neither Parent nor any of its Affiliates shall (a)&nbsp;purchase any shares of
Company Common Stock or any security of the Company that is convertible into Company Common Stock
in the open market or in privately negotiated transactions or (b)&nbsp;form, join or in any way
participate in a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act) in connection with
any of the foregoing or (c)&nbsp;prior to the termination of this Agreement, commence a tender offer or
exchange offer at a price per share below the Merger Consideration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.12 <U>Notification of Certain Events</U>. The Company will notify Parent and
Merger Sub, and Parent and Merger Sub will notify the Company, promptly of (a)&nbsp;any material written
communications from any Person alleging that the consent of such Person is or may be required in
connection with the transactions contemplated by this Agreement, provided that the foregoing shall
not apply in respect of any immaterial consents, (b)&nbsp;any written communication from any
Governmental Entity in connection with the transactions contemplated by this Agreement (other than
any such communication from a Governmental Entity in its capacity as a counterparty to any contract
with the Company thereof), (c)&nbsp;any legal, administrative, arbitral or other proceedings, claims or
actions commenced against the Company or Parent or their respective Subsidiaries or the Affiliated
Medical Practices, as applicable, that are related to the transactions contemplated by this
Agreement and (d)&nbsp;any event, change or effect between the date of this Agreement and the Effective
Time which causes or is reasonably likely to cause the conditions set forth in
<U>Sections&nbsp;6.02(a)</U> or <U>6.02(b)</U> of this Agreement (in the case of the Company) or
<U>Sections&nbsp;6.03(a)</U> or <U>6.03(b)</U> of this Agreement (in the case of Parent and its
Subsidiaries).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.13 <U>Takeover Statutes</U>. If any Takeover Statute becomes or is deemed to be
applicable to the Company, Parent, Merger Sub, the Merger or any other transaction contemplated by
this Agreement, then each of the Company, Parent, Merger Sub, and their respective Boards of
Directors shall grant such
approvals and take such actions as are necessary so that the transactions contemplated hereby
may be consummated as promptly as practicable on the terms contemplated hereby and otherwise act to
render such Takeover Statute inapplicable to the foregoing. &#147;<U>Takeover Statute</U>&#148; shall mean
any restrictive provision of any applicable &#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share
acquisition,&#148; &#147;interested stockholder&#148; or other similar anti-takeover Law, including Section&nbsp;203 of
the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.14 <U>Section&nbsp;16 Matters</U>. Prior to the Effective Time, the Company Board shall
take all such steps as may be required and permitted to cause the transactions contemplated by this
Agreement, including any dispositions of shares of Company Common Stock (including derivative
securities with respect to such Company Common Stock) by each individual who is or will be subject
to the reporting requirements of Section 16(a) of the Exchange Act with respect to the Company, to
be exempt under Rule&nbsp;16b-3 promulgated under the Exchange Act.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.15 <U>Delisting</U>. Each of the parties agrees to cooperate with each other in
taking, or causing to be taken, all actions necessary to delist the Company Common Stock from the
Nasdaq Stock Market and terminate registration under the Exchange Act, provided that such delisting
and termination shall not be effective until or after the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.16 <U>Additional Agreements</U>. In case at any time after the Effective Time any
further action is necessary or desirable to carry out the purposes of this Agreement or to vest the
Surviving Corporation with full title to all properties, assets, rights, approvals, immunities and
franchises of either of the Company or Merger Sub, the proper officers and directors of each party
to this Agreement shall use reasonable best efforts to take all such necessary action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5.17 <U>Cooperation with Financing</U>. If Parent determines to seek financing
(through loans from financial institutions or otherwise) in connection with the transactions
contemplated hereby (each a &#147;Parent Financing&#148;), the Company shall, and shall cause its
Subsidiaries, the Affiliated Medical Practices and its and their directors, officers, employees,
accountants, agents, advisors and other representatives to, reasonably cooperate with Parent in
connection therewith and use their commercially reasonable efforts to take all actions reasonably
requested by Parent in connection therewith (in each case, at Parent&#146;s expense), including (a)
participating in marketing efforts (including lender meetings and calls), due diligence sessions
and rating agency presentations; (b)&nbsp;assisting Parent in its preparation of rating agency
presentations, bank books, confidential information memoranda or similar documents; (c)&nbsp;delivering
to Parent information with respect to the Company, its Subsidiaries and the Affiliated Medical
Practices as is reasonably requested in connection with the Parent Financing, including, at the
request of Parent, delivery within 15&nbsp;days of the close of each fiscal month, monthly financial
statements of the Company, its Subsidiaries and the Affiliated Medical Practices (including a
balance sheet and income statement); (d)&nbsp;facilitating the pledge and perfection of liens securing
the Parent Financing; and (e)&nbsp;taking all other actions
as are reasonably requested by Parent to facilitate the satisfaction on a timely basis of all
conditions to obtaining the Parent Financing; <U>provided</U>, <U>however</U>, that the
cooperation and actions required by the Company pursuant to this <U>Section&nbsp;5.17</U> shall not
unreasonably interfere with the ordinary course operation of the Company&#146;s, its Subsidiaries&#146; or
the Affiliated Medical Practices&#146; businesses.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI<BR>
CONDITIONS TO CLOSING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 6.01 <U>Conditions to Each Party&#146;s Obligation to Effect the Merger</U>. The
respective obligations of each party to effect the Merger shall be subject to the satisfaction at
or prior to the Effective Time of the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Stockholder Approval</U>. This Agreement shall have been adopted by the Company
Required Vote.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>HSR Compliance</U>. Any waiting period (or extension thereof) applicable to the
consummation of the Merger under the HSR Act shall have expired or been terminated and all
regulatory clearances in any relevant jurisdiction shall have been obtained in respect of the
Merger and the other transactions contemplated hereby.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>No Order</U>. No Governmental Entity of competent jurisdiction shall have (i)&nbsp;enacted
a Law that is in effect and renders the Merger illegal in the United States or any State thereof,
or (ii)&nbsp;formally issued an injunction that is in effect and prohibits the Merger in the United
States or any State thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 6.02 <U>Conditions to Obligations of Parent and Merger Sub</U>. The obligations of
Parent and Merger Sub to effect the Merger are also subject to the satisfaction or waiver at or
prior to the Effective Time of the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Representations and Warranties</U>. The(i) representations and warranties set forth
in <U>Section&nbsp;3.01</U> (Corporate Organization), <U>3.02(a</U>) and <U>(c</U>) (Capitalization),
<U>3.03(a</U>) (Authority); and <U>3.07</U> (Broker&#146;s Fees) shall be true and correct in all
respects and (ii)&nbsp;other representations and warranties of the Company set forth in this Agreement
shall be true and correct in all respects as of the date of this Agreement and (except to the
extent such representations and warranties speak as of an earlier date) as of the Closing Date as
though made on and as of the Closing Date; <U>provided</U>, <U>however</U>, that for purposes of
determining the satisfaction of the condition in clause (ii), no effect shall be given to any
exception in such representations and warranties relating to materiality or a Company Material
Adverse Effect, and such representations and warranties shall be deemed to be true and correct in
all respects unless the failure or failures of such representations and warranties to be so true
and correct, individually or in the aggregate, results or would be reasonably likely to result in a
Company Material Adverse Effect. Parent shall have received a certificate signed on behalf of the
Company by its Chief Executive Officer and Chief Financial Officer to the foregoing effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Performance of Obligations</U>. The Company shall have performed in all material
respects all obligations required to be performed by it under this Agreement at or prior to the
Closing Date, and Parent shall have received a certificate signed on behalf of the Company by its
Chief Executive Officer and Chief Financial Officer to such effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Absence of a Company Material Adverse Effect</U>. Since December&nbsp;31, 2009, there
shall not have been any change, effect, event, circumstance, condition, occurrence or development
that, individually or in the aggregate, has had or would be reasonably likely to have a Company
Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 6.03 <U>Conditions to Obligations of the Company</U>. The obligation of the Company
to effect the Merger is also subject to the satisfaction or waiver at or prior to the Effective
Time of the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Representations and Warranties</U>. The representations and warranties of Parent and
Merger Sub set forth in this Agreement shall be true and correct in all respects as of the date of
this Agreement and (except to the extent such representations and warranties speak as of an earlier
date) as of the Closing Date as though made on and as of the Closing Date; <U>provided</U>,
<U>however</U>, that for purposes of determining the satisfaction of this condition, no effect
shall be given to any exception in such representations and warranties relating to materiality or a
Parent Material Adverse Effect; <U>provided</U>, <U>further</U>, that, for purposes of this
condition, such representations and warranties shall be deemed to be true and correct in all
respects unless the failure or failures of such representations and warranties to be so true and
correct, individually or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in the aggregate, results or would result in a Parent Material Adverse
Effect. The Company shall have received a certificate signed on behalf of Parent by its Chief
Executive Officer and Chief Financial Officer to the foregoing effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Performance of Obligations</U>. Each of Parent and Merger Sub shall have performed in
all material respects all of its respective obligations required to be performed by it under this
Agreement at or prior to the Closing Date, and the Company shall have received a certificate signed
on behalf of Parent by its Chief Executive Officer and Chief Financial Officer to such effect.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII<BR>
TERMINATION OF AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7.01 <U>Termination</U>. This Agreement may be terminated and the Merger and the
other transactions contemplated hereby may be abandoned at any time prior to the Effective Time
(notwithstanding if the Company Required Vote has been obtained or Parent has adopted this
Agreement as the sole stockholder of Merger Sub):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;by the mutual written consent of the Company and Parent;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;by the Company or Parent, in the event that any Governmental Entity of competent
jurisdiction shall have (i)&nbsp;enacted a Law that is in effect at the time of such
termination and renders the Merger illegal in the United States or any State thereof at the
time of such termination, or (ii)&nbsp;formally issued a permanent, final and non-appealable injunction,
ruling, decree or order that prohibits the Merger in the United States or any State thereof;
<U>provided</U>, <U>however</U>, that the party seeking to terminate this Agreement pursuant to
this clause (b)&nbsp;shall not have initiated such proceeding or taken any action in support of such
proceeding;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;by the Company or Parent, if at the Company Stockholder Meeting (giving effect to any
adjournment or postponement thereof), the Company Required Vote shall not have been obtained;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;at any time prior to the Company Required Vote having been obtained by the Company in
order to enter into an acquisition agreement for a Superior Proposal; <U>provided</U>,
<U>however</U>, that this Agreement may not be so terminated unless (i)&nbsp;the Company shall have
complied with the procedures set forth in <U>Section&nbsp;5.06</U> and <U>Section&nbsp;5.10</U> and (ii)
the payment required by <U>Section&nbsp;7.02</U> has been made in full to Parent;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;by Parent if (i)&nbsp;there shall have been a Company Recommendation Change, or (ii)&nbsp;the
Company shall have knowingly and materially breached any of its obligations under <U>Section
5.06</U> or <U>Section&nbsp;5.10</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;by the Company or Parent, if the Merger shall not have been consummated prior to November
30, 2010 (the &#147;<U>Outside Termination Date</U>&#148;); <U>provided</U>, <U>however</U>, that the
right to terminate this Agreement pursuant to this <U>Section&nbsp;7.01(f)</U> shall not be available
to any party hereto whose actions or omissions have primarily been the cause of, or resulted in,
either (A)&nbsp;the failure to satisfy the conditions to the obligations of the terminating party to
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">consummate the Merger set forth in <U>Article&nbsp;VI</U> prior to the Outside Termination Date, or (B)
the failure of the Effective Time to have occurred prior to the Outside Termination Date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;by Parent, if there shall have been any breach of any representation or warranty, or any
such representation or warranty of the Company shall have become untrue and incapable of being
cured prior to the Effective Time, or any breach of any covenant or agreement of the Company
hereunder, such that a condition in <U>Section&nbsp;6.02(a)</U> or <U>Section&nbsp;6.02(b)</U> would not be
satisfied, and such breach or condition is not curable or, if curable, shall not have been remedied
within thirty (30)&nbsp;days after receipt by the Company of notice in writing from Parent, specifying
the nature of such breach and requesting that it be remedied; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;by Company, if there shall have been any breach of any representation or warranty, or any
such representation or warranty of Parent or Merger Sub shall have become untrue and incapable of
being cured prior to the Effective Time, or any breach of any covenant or agreement of Parent or
the Merger Sub hereunder, such that a condition in <U>Section&nbsp;6.03(a)</U> or <U>Section
6.03(b)</U> would not be satisfied, and such breach or condition is not curable or, if curable,
shall not have been remedied within thirty (30)&nbsp;days after receipt by Parent of notice in writing
from the Company, specifying the nature of such breach and requesting that it be remedied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The party desiring to terminate this Agreement pursuant to subsections <U>(b)</U>,
<U>(c)</U>, <U>(d)</U>, <U>(e)</U>, <U>(f)</U>, <U>(g)</U> or <U>(h)</U> of this <U>Section
7.01</U> shall give written notice of such termination to the other party in accordance with
<U>Article&nbsp;VIII</U>, specifying the provision or provisions hereof pursuant to which
termination is effected. The right of any party hereto to terminate this Agreement pursuant
to this <U>Section&nbsp;7.01</U> shall remain operative and in full force and effect regardless of any
investigation made by or on behalf of any party hereto, or any of their respective Affiliates or
representatives, whether prior to or after the execution of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7.02 <U>Company Termination Fee</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;If this Agreement is terminated (i)&nbsp;by the Company pursuant to <U>Section&nbsp;7.01(d)</U> or
(ii)&nbsp;by Parent or the Company, as applicable, pursuant to <U>Section&nbsp;7.01(c)</U>, <U>7.01(e)</U>,
<U>7.01(f)</U> (unless the actions or omissions of Parent or Merger Sub have been the primary
cause of, or resulted in either (A)&nbsp;the failure to satisfy the conditions to the obligations of the
Company to consummate the Merger set forth in <U>Article&nbsp;VI</U> prior to the Outside Termination
Date, or (B)&nbsp;the failure of the Effective Time to have occurred prior to the Outside Termination
Date) or <U>7.01(g)</U>, the Company shall pay Parent or its designee the Company Termination Fee
by wire transfer of immediately available funds; (x)&nbsp;in the case of any termination pursuant to
clause (i)&nbsp;above, prior to or contemporaneous with such termination, and (y)&nbsp;in the case of any
termination pursuant to clause (ii)&nbsp;above, only if (A)&nbsp;prior to such termination but after the date
hereof, an Acquisition Proposal is made known to the Company or publicly announced by any Person
(other than Parent, Merger Sub or their respective Affiliates) and (B)&nbsp;an Acquisition Proposal is
consummated or the Company enters into an acquisition agreement for an Acquisition Proposal with
any Person, in any case, within twelve (12)&nbsp;months following such termination, in which case such
payment shall be made prior to or contemporaneous with the consummation of, or entering into an
acquisition agreement for, an Acquisition Proposal. For the avoidance of doubt, in no event shall
the Company be obligated to pay, or cause to be paid, the Company Termination Fee on more than one
(1)&nbsp;occasion.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event that this Agreement is terminated pursuant to <U>Section&nbsp;7.01(c</U>) or
<U>Section&nbsp;7.01(g</U>), the Company shall reimburse Parent or its designee for the documented
reasonable out-of-pocket fees and expenses incurred by Parent, Merger Sub or any of their
Affiliates in connection with this Agreement or the transactions contemplated hereby up to an
aggregate amount of $2,400,000, by wire transfer of immediately available funds not later than five
(5)&nbsp;Business Days after delivery to the Company of an itemization setting forth in reasonable
detail all such reimbursable expenses; provided that any amounts paid by the Company of Parent
pursuant to this <U>Section&nbsp;7.02(b</U>) shall reduce on a dollar-for-dollar basis any Company
Termination Fee that becomes due and payable pursuant to <U>Section&nbsp;7.02(a</U>). The parties
acknowledge that (i)&nbsp;the agreements contained in this <U>Section&nbsp;7.02</U> are an integral part of
the transactions contemplated in this Agreement, (ii)&nbsp;the damages resulting from termination of
this Agreement under circumstances where a Company Termination Fee is payable are uncertain and
incapable of accurate calculation and therefore, the amounts payable pursuant to <U>Section
7.02(a)</U> are not a penalty but rather constitute liquidated damages in a reasonable amount that
will compensate Parent for the efforts and resources expended and opportunities foregone while
negotiating this Agreement and in reliance on this Agreement and on the expectation of the
consummation of the transactions contemplated hereby, and (iii)&nbsp;without the agreements contained in
this <U>Section&nbsp;7.02</U>, the parties would not have entered into this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7.03 <U>Effect of Termination</U>. In the event of termination of this Agreement by either Parent or the Company as provided
in this <U>Article&nbsp;VII</U>, this Agreement shall forthwith become void and have no effect, and
none of Parent, Merger Sub, the Company, any of their respective Subsidiaries or any of the
officers or directors of any of them shall have any liability of any nature whatsoever hereunder,
or in connection with the transactions contemplated hereby; <U>provided</U>, <U>however</U>, that
(i) <U>Sections&nbsp;5.01(b)</U>, <U>Article&nbsp;VII</U>, <U>Article&nbsp;VIII</U>, and <U>Article&nbsp;IX</U>
and, in accordance with its terms, the Guarantee shall survive any termination of this Agreement
and (ii)&nbsp;Subject to <U>Section&nbsp;9.09</U>, neither Parent, Merger Sub nor the Company shall be
relieved or released from any liabilities or damages arising out of its knowing and material breach
of this Agreement; <U>provided</U>, <U>however</U>, that receipt of the Company Termination Fee
as provided herein shall be the sole and exclusive remedy of Parent and Merger Sub under
circumstances where the Termination Fee is payable by the Company.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII<BR>
NOTICES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice required or permitted under this Agreement shall be given in writing and shall be
deemed effectively given upon personal delivery to the party to be notified, on the next Business
Day after delivery to a nationally recognized overnight courier service, when sent by confirmed
facsimile if sent during normal business hours of the recipient, if not, then on the next Business
Day, or five (5)&nbsp;days after deposit with the United States Post Office, by registered or certified
mail, postage prepaid, and addressed to the party to be notified at the address or facsimile number
indicated below for such party, or at such other address as such party may designate upon written
notice to the other parties (except that notice of change of address shall be deemed given upon
receipt).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the case of Parent or Merger Sub:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">c/o Providence Equity Partners L.L.C.<BR>
50 Kennedy Plaza, 18th Floor<BR>
Providence, RI 02903<BR>
Attn: Peter O. Wilde<BR>
Facsimile: (401)&nbsp;751-1790
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">c/o Providence Equity Partners L.L.C.<BR>
9 West 57th Street, Suite&nbsp;4700<BR>
New York, NY 10019<BR>
Attn: Jesse M. Du Bey<BR>
Facsimile: (212)&nbsp;644-1200
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>with a copy to</I>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Weil, Gotshal &#038; Manges LLP<BR>
50 Kennedy Plaza, 11th Floor<BR>
Providence, RI 02903<BR>
Attn: David K. Duffell, Esq.<BR>
Facsimile: (401)&nbsp;278-4701
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Weil, Gotshal &#038; Manges LLP<BR>
767 Fifth Avenue<BR>
New York, NY 10153<BR>
Attn: Michael E. Weisser, Esq.<BR>
Facsimile: (212)&nbsp;310-8007
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the case of the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Virtual Radiologic Corporation<BR>
11995 Singletree Lane, Suite&nbsp;500<BR>
Eden Prairie, MN 55344<BR>
Attn: Michael Kolar, General Counsel<BR>
Facsimile: (952)&nbsp;938-1662
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>with a copy to</I>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Oppenheimer Wolff &#038; Donnelly LLP<BR>
Plaza VII, Suite&nbsp;3300<BR>
45 South Seventh Street<BR>
Minneapolis, MN 55402<BR>
Attn: Bruce Machmeier, Esq. and William McDonald, Esq.<BR>
Facsimile: (612)&nbsp;607-7100
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX<BR>
MISCELLANEOUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.01 <U>Non-survival of Representations and Warranties</U>. None of the
representations and warranties in this Agreement or in any instrument delivered pursuant to this
Agreement shall survive the Effective Time. This <U>Section&nbsp;9.01</U> shall not limit any covenant
or agreement of the parties in this Agreement that by its terms contemplates performance after the
Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.02 <U>Publicity</U>. Parent, Merger Sub and the Company shall consult with each
other before issuing any press release with respect to the Merger or this Agreement and shall not
issue any such press release or make any such public statement without the prior consent of the
other party, which shall not be unreasonably withheld or delayed; <U>provided</U>,
<U>however</U>, that a party may, without the prior consent of the other party (but after prior
consultation, to the extent practicable in the circumstances) issue such press release or make such
public statement or SEC filing as may upon the advice of outside counsel be required by Law or the
rules and regulations of any applicable stock exchange (including the Nasdaq Stock Market). The
parties have agreed upon the form of a joint press release announcing the Merger and the execution
of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.03 <U>Expenses</U>. Except as otherwise provided in this Agreement, each party
will bear its own expenses and costs incurred in connection with this Agreement and the
transactions contemplated hereby, whether or not such transactions will be consummated (for the
sake of clarity, Parent shall be responsible for the HSR Act filing fees).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.04 <U>Entire Agreement</U>. This Agreement, together with the Exhibits and
Schedules annexed hereto, the Guarantee and the Voting Agreement, constitutes the entire
understanding and agreement by and among the parties hereto with respect to the subject matter
hereof, and supersedes all prior negotiations, agreements and understandings among such parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.05 <U>Assignment; Third Party Beneficiaries</U>. Neither this Agreement nor any of
the rights, interests or obligations of any party hereunder shall be assigned by any of the parties
hereto (whether by operation of Law or otherwise) without the prior written consent of the other
party. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit
of and be enforceable by the parties and their respective successors and permitted assigns. Except
as otherwise specifically provided in <U>Section&nbsp;5.09</U> (Indemnification; Directors&#146; and
Officers&#146; Insurance) or <U>Section&nbsp;9.09</U> (Enforcement), this Agreement (including the documents
and instruments referred to herein) is not intended to confer upon any Person other than the
parties hereto any rights or remedies hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.06 <U>Governing Law</U>. This Agreement, including the validity hereof and the
rights and obligations of the parties hereunder, and all amendments and supplements hereof and all
waivers and consents hereunder, shall be construed in accordance with and governed by the domestic
substantive laws of the State of Delaware without giving effect to any choice of law or conflicts
of law provision or rule that would cause the application of the domestic substantive laws of any
other jurisdiction. The parties hereto hereby irrevocably submit to the non-exclusive
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">jurisdiction
of any federal or state court located within the State of Delaware over any dispute arising out of
or relating to this Agreement or any of the transactions contemplated hereby and each party hereby
irrevocably agrees that all claims in respect of such dispute or any suit, action or proceeding
related thereto may be heard and determined in such courts. The parties hereby irrevocably waive,
to the fullest extent permitted by applicable Law, any objection which they may now or hereafter
have to the laying of venue of any such dispute brought in such court or any defense of
inconvenient forum for the maintenance of such dispute. Each of the parties hereto agrees that a
judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in
any other manner provided by Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.07 <U>Waiver of Jury Trial</U>. Each party acknowledges and agrees that any
controversy which may arise under this Agreement is likely to involve complicated and difficult
issues and, therefore, each such party irrevocably and unconditionally waives any right it may have
to a trial by jury in respect of any legal action arising out of or relating to this Agreement or
the transactions contemplated by this Agreement. Each party to this Agreement certifies and
acknowledges that (a)&nbsp;no representative of any other party has represented, expressly or otherwise,
that such other party would not seek to enforce the foregoing waiver in the event of a legal
action, (b)&nbsp;such party has considered the implications of this waiver, (c)&nbsp;such party makes this
waiver voluntarily, and (d)&nbsp;such party has been induced to enter into this Agreement by, among
other things, the mutual waivers and certifications in this <U>Section&nbsp;9.07</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.08 <U>Severability</U>. Any term or provision of this Agreement that is invalid or
unenforceable shall not affect the validity or enforceability of the remaining terms and provisions
hereof. If the final judgment of a court of competent jurisdiction declares that any term or
provision hereof is invalid, illegal or unenforceable, the parties hereto agree that the court
making such determination shall have the power to limit the term or provision, to delete specific
words or phrases, or to replace any invalid, illegal or unenforceable term or provision with a term
or provision that is valid, legal and enforceable and that comes closest to expressing the
intention of the invalid, illegal or unenforceable term or provision, and this Agreement shall be
enforceable as so modified. In the event such court does not exercise the power granted to it in
the prior sentence, the parties hereto agree to replace such invalid, illegal or unenforceable term
or provision with a valid, legal and enforceable term or provision that will achieve, to the extent
possible, the economic, business and other purposes of such invalid, illegal or unenforceable term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.09 <U>Enforcement</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The parties agree that irreparable damage would occur in the event that any provision of
this Agreement were not performed in accordance with the terms hereof and that Company, Parent and
Merger Sub shall be entitled to specific performance of the terms and provisions hereof (including
the obligation to consummate the Merger, subject in each case to the terms and conditions of this
Agreement), including an injunction or injunctions to prevent breaches of this Agreement by the
Company, Parent or Merger Sub, in addition to any other remedy at law or equity. The Company,
Parent and Merger Sub each hereby waive (a)&nbsp;any defenses in any action for specific performance,
including the defense that a remedy at Law would be adequate and (b)&nbsp;any requirement under any Law
to post a bond or other security as a prerequisite to obtaining equitable relief. In addition,
notwithstanding anything to the contrary in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">this Agreement, Parent acknowledges and agrees that in
the event of any breach or wrongful repudiation of this Agreement by Parent or Merger Sub, the
actual damages incurred by the Company for purposes of determining damages to the extent available
as a remedy to the Company under <U>Section&nbsp;9.09(c</U>) would include the actual damages incurred
by the Company&#146;s stockholders in the event such stockholders would not receive the benefit of the
bargain negotiated by the Company on their behalf as set forth in this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company hereby agrees that specific performance as provided for in <U>Section
9.09(a</U>) shall be its sole and exclusive remedy with respect to breaches by Parent, Merger Sub,
or any other Person or otherwise in connection with this Agreement or the transactions contemplated
hereby (whether in contract, tort or otherwise) and except as provided in <U>Section&nbsp;9.09(c</U>)
below, that it may not seek or accept any other form of relief that may be available for breach
under this Agreement or otherwise in connection with this Agreement or the transactions
contemplated hereby (including monetary damages).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If a court of competent jurisdiction has declined to specifically enforce the obligations
of Parent to consummate the Merger pursuant to a claim for specific performance brought against
Parent pursuant to this <U>Section&nbsp;9.09</U> and has instead granted an award of damages for such
alleged breach against Parent, the Company may enforce such award and accept damages for such
alleged breach only if, within two (2)&nbsp;weeks following such determination the Company confirms to
Parent in writing that it is prepared and willing to consummate the Merger in accordance with this
Agreement, and Parent is not willing to consummate the Merger within such two (2)&nbsp;week period in
accordance with the terms and conditions of this Agreement. In addition, the Company agrees to
cause any legal proceeding still proceeding to be dismissed with prejudice at such time as Parent
consummates the Merger in accordance with Article&nbsp;II of this Agreement or is otherwise willing to
do so.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.10 <U>Captions</U>. The headings and captions used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.11 <U>Certain References</U>. Whenever the context may require, any pronoun used in this Agreement shall include the
corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns and
verbs shall include the plural and vice versa. The terms &#147;herein&#148;, &#147;hereof&#148; or &#147;hereunder&#148; or
similar terms as used in this Agreement refer to this entire Agreement and not to the particular
provision in which the term is used. Unless otherwise stated, all references herein to Articles,
Sections, subsections or other provisions are references to Articles, Sections, subsections or
other provisions of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.12 <U>Guaranty by Parent</U>. By its signature below, Parent hereby guarantees the
obligations of Merger Sub pursuant to this Agreement to be performed on or prior to the Closing
Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.13 <U>Counterparts</U>. This Agreement may be executed by facsimile or portable
document format (pdf)&nbsp;transmission and in separate counterparts, each such counterpart being deemed
to be an original instrument, and all such counterparts will together constitute the same
agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.14 <U>Amendment or Supplement</U>. At any time prior to the Effective Time, this
Agreement may be amended or supplemented in any and all respects, whether before or after receipt
of the Company Required Vote, by written agreement of the parties hereto, by action taken by their
respective Boards of Directors; <U>provided</U>, <U>however</U>, that following approval of the
Merger by the Stockholders, there shall be no amendment or change to the provisions hereof which by
Law would require further approval by the Stockholders without such approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.15 <U>Defined Terms</U>. The following terms used in this Agreement shall have the
following meanings or the meanings set forth in the corresponding Sections or subsections of this
Agreement:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Acquisition Proposal</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.10(d)(i)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Affiliate</u>&#148; means with respect to any Person, any other
Person that, directly or indirectly through one or more
intermediaries, controls, or is controlled by, or is under
common control with, such Person, and the term &#147;control&#148;
(including the terms &#147;controlled by&#148; and &#147;under common
control with&#148;) means the possession, directly or
indirectly, of the power to direct or cause the direction
of the management and policies of such Person, whether
through owners of voting securities, by contract or
otherwise.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Affiliated Medical Practices</u>&#148; means, collectively, the
following Persons: Virtual Radiologic Professionals, LLC,
Virtual Radiologic Professionals of California, P.A.,
Virtual Radiologic Professionals of Illinois, S.C.,
Virtual Radiologic Professionals of Michigan, P.C.,
Virtual Radiologic Professionals of Minnesota, P.A.,
Virtual Radiologic Professionals of New York, P.A., and
Virtual Radiologic Professionals of Texas, P.A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Aggregate Consideration</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Agreement</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Bankruptcy and Equity Exceptions</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.03(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Business Day</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.02
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Capitalization Date</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Certificate</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Certificate of Merger</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.03
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Claim</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.09(a)
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Closing</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.02
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Closing Date</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.02
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Code</u>&#148; means the Internal Revenue Code of 1986, as amended.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Benefit Plans</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.11(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Board</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.01(d)(iii)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Common Stock</u>&#148; means the common stock, par value
$0.001 per share, of the Company.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Contract</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.13(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Disclosure Schedule</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Article&nbsp;III
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Material Adverse Effect</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.01(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Preferred Stock</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Recommendation</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.06
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Recommendation Change</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.10(b)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Representatives</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.10(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Required Vote</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.03(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Restricted Stock</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.01(d)(ii)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company SEC Reports</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.05
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Stock Option</u>&#148; means each option to purchase a
share of Company Common Stock, which option is issued and
outstanding immediately prior to the Effective Time.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Stock Plans</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Stockholder Meeting</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.06
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Company Termination Fee</u>&#148; means $9,000,000.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Confidentiality Agreement</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.01(b)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Continuing Employees</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.08(a)
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>DGCL</u>&#148; means the Delaware General Corporation Law, as
amended.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Dissenting Shares</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.05(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Effective Time</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.03
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Environmental Law</u>&#148; means any foreign, federal, state or
local statute, regulation, ordinance, rule of common law
or other legal requirement, as now or hereafter in effect,
in any way relating to the protection of human health and
safety, the environment or natural resources including,
without limitation, the Comprehensive Environmental
Response, Compensation and Liability Act (42 U.S.C. &#167; 9601
et seq.), the Hazardous Materials Transportation Act (49
U.S.C. App. &#167; 1801 et seq.), the Resource Conservation and
Recovery Act (42 U.S.C. &#167; 6901 et seq.), the Clean Water
Act (33 U.S.C. &#167; 1251 et seq.), the Clean Air Act (42
U.S.C. &#167; 7401 et seq.) the Toxic Substances Control Act
(15 U.S.C. &#167; 2601 et seq.), the Federal Insecticide,
Fungicide, and Rodenticide Act (7 U.S.C. &#167; 136 et seq.),
and the Occupational Safety and Health Act (29 U.S.C. &#167;
651 et seq.), as each has been or may be amended and the
regulations promulgated pursuant thereto.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Environmental Permits</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.19(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>ERISA</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.11(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Exchange Act</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.05
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Exchange Fund</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Expenses</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.09(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Federal Health Care Program</u>&#148; means any plan or program
that provides health benefits, whether directly, through
insurance, or otherwise, which is funded directly, in
whole or in part, by the United States Government, or any
state health care program either approved under the Social
Security Act or receiving federal funds.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>GAAP</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.01(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Governmental Entity</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.04
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Guarantee</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Preamble
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Guarantors</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>HSR Act</u>&#148; means the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Indebtedness</u>&#148; of any Person means, without duplication,
(i)&nbsp;the principal of, accrued interest of, premium (if
any) in respect of and prepayment and other penalties,
charges, expenses and fees associated with (A)
indebtedness of such Person for money borrowed and (B)
indebtedness evidenced by notes, debentures, bonds or
other similar instruments for the payment of which such
Person is responsible or liable; (ii)&nbsp;all obligations of
such Person issued or assumed as the deferred purchase
price of property, all conditional sale obligations of
such Person and all obligations of such Person under any
title retention agreement (but excluding trade accounts
payable and other accrued current liabilities arising in
the ordinary course of business consistent with past
practice); (iii)&nbsp;all obligations of such Person for the
reimbursement of any obligor on any letter of credit,
banker&#146;s acceptance or similar credit transaction; (iv)
all obligations of the type referred to in clauses (i)
through (iii)&nbsp;of other Persons for the payment of which
such Person is responsible or liable, directly or
indirectly, as obligor, guarantor, surety or otherwise,
including guarantees of such obligations; and (vi)&nbsp;all
obligations of the type referred to in clauses (i)&nbsp;through
(v)&nbsp;of other Persons secured by any Lien on any property
or asset of such Person (whether or not such obligation is
assumed by such Person).</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Indemnified Parties</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.09(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Intellectual Property Rights</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.20
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>IRS</u>&#148; means the Internal Revenue Service.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Knowledge of the Company</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="left" valign="top">3.09</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Knowledge of Parent</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top">4.04</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Law</u>&#148; means any federal, state, local or foreign law
(including common law), statute, code, ordinance, rule,
regulation or other requirement.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Liens</u>&#148; means any lien, encumbrance, security interest,
charge, pledge, mortgage, deed of trust, claim, lease,
option, right of first refusal, easement, servitude or
transfer restriction, except for (a)&nbsp;liens for current
Taxes not yet due and payable or for Taxes the validity of
which is being contested in good faith by appropriate
proceedings and for which adequate reserves have been
established on the latest audited financial statements in
accordance with GAAP, and (b)&nbsp;liens to secure indebtedness
reflected on the Company&#146;s most recent balance sheet or
indebtedness incurred in the Ordinary Course of Business
after the date thereof.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Merger</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.01
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Merger Consideration</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.01(b)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Merger Sub</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Notice Period</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.10(b)(i)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Option Consideration</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.01(d)(i)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Optionholder</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.01(d)(i)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Ordinary Course of Business</u>&#148; means, with respect to any
Person, the ordinary and usual course of business of such
Person consistent with past practices.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>OSHA</u>&#148; means the Occupational Safety and Health
Administration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Other Filings</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.05(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Outside Termination Date</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;7.01(f)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Parent</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Parent Disclosure Schedule</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Article&nbsp;IV
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Parent Financing</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.17
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Parent Material Adverse Effect</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;4.01
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Parent Plans</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.08(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Paying Agent</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;2.02(a)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Permits</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.12(b)
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Permitted Liens</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.17(c)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Person</u>&#148; means any individual, corporation, partnership,
firm, joint venture, association, joint-stock company,
trust, unincorporated organization, Governmental Entity or
other entity.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt"><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Proxy Statement</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.04
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>SEC</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Article&nbsp;III
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Securities Act</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.05
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Stockholder</u>&#148; means the holders of the Company Common
Stock.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Subsidiary</u>&#148; means, with respect to Company, Parent or
Merger Sub, as the case may be, any entity, whether
incorporated or unincorporated, of which at least a
majority of the securities or ownership interests having
by their terms ordinary voting power to elect a majority
of the board of directors or other Persons performing
similar functions is directly or indirectly owned or
controlled by such party or by one or more of its
respective Subsidiaries or by such party and any one or
more of its respective Subsidiaries.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Superior Proposal</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.10(d)(ii)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Surviving Corporation</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;1.01
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Takeover Statute</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;5.13
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Tax Return</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.10(h)
</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;<u>Taxes</u>&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="left" valign="top">Section&nbsp;3.10(g)
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9.16 <U>Interpretation</U>. This Agreement shall be construed reasonably to carry
out its intent without presumption against or in favor of either party.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page Follows</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>MERGER SUB:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>VIKING ACQUISITION CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD  colspan="3" align="left" valign="top" style="border-bottom: 1px solid #000000">/s/ Jesse Du Bey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jesse Du Bey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>PARENT:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>VIKING HOLDINGS LLC</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3"  align="left" valign="top" style="border-bottom: 1px solid #000000">/s/ Jesse Du Bey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jesse Du Bey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature Page to Agreement and Plan of Merger&#093;</I>
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>COMPANY:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>VIRTUAL RADIOLOGIC CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3"  align="left" valign="top" style="border-bottom: 1px solid #000000">/s/ Robert C. Kill</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert C. Kill</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Chairman of the Board, President and<br>Chief Executive Officer </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature Page to Agreement and Plan of Merger&#093;</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
